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Abstract: Several recent studies have emphasized a crucial role for the interactions between serotonergic
and dopaminergic systems in movement control and the pathophysiology of basal ganglia. These
observations are supported by anatomical evidence demonstrating large serotonergic innervation of all the
basal ganglia nuclei. In fact, serotonergic terminals have been reported to make synaptic contacts with both
substantia nigra dopamine-containing neurons and their terminal areas such as the striatum, the globus
pallidus and the subthalamus. These brain areas contain a high concentration of serotonin (5-HT), with the
substantia nigra pars reticulata receiving the greatest input. In this chapter, the distribution of different
5-HT receptor subtypes in the basal ganglia nuclei will be described. Furthermore, evidence demonstrating
the serotonergic control of basal ganglia activity will be reviewed and the contribution of the different 5-HT
receptor subtypes examined. The new avenues that the increasing knowledge of 5-HT in motor control has
opened for exploring the pathophysiology and pharmacology of Parkinson’s disease and other movement
disorders will be discussed. It is clear that these avenues will be fruitful, despite the disappointing results so
far obtained by clinical studies with selective 5-HT ligands. Nevertheless, these studies have led to a great
increase in the attention given to the neurotransmitters of the basal ganglia and their connections.
Keywords: serotonergic receptors; basal ganglia; Parkinson’s disease; motor disorders; dyskinesia; selective
5-HT drugs
Introduction
Since the 1950s, when serotonin (5-HT) was
discovered in the mammalian central nervous
system (CNS), an enormous amount of experi-
mental evidence has revealed the pivotal role of
this biogenic amine in a bewildering diversity of
behavioural and physiological processes. This is
not surprising, considering the almost ubiquitous
distribution of 5-HT-containing axon terminals
throughout the CNS, although 5-HT is synthe-
sized by a small group of neurons within the raphe
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nuclei of the brain stem. Despite this broad axon-
terminal domain of 5-HT neurons, a closer
examination reveals a preferential targeting of
motor areas in the CNS (Steinbusch, 1981). For
example, in the rat, there is a very dense
innervation of the ventral horn of the spinal cord,
the motor nucleus of the trigeminal, the facial
motor nucleus and all components of the basal
ganglia circuitry (Lavoie and Parent, 1990). It is
thus likely that 5-HT plays a role in regulating the
appropriate selection of voluntary movements by
the basal ganglia, and abnormalities in 5-HT
transmission might contribute to the neural
mechanisms underlying disorders of basal ganglia
origin, such as Parkinson’s disease (PD), Tour-
ette’s syndrome and obsessive compulsive disorder
(Chapter 24; Ring and Serra-Mestre, 2002).
Indeed, biochemical evidence suggests that 5-HT
transmission is abnormal in the basal ganglia of
patients with PD (Hornykiewicz, 1998) and, more-
over, in the movement abnormalities generally
associated with the use of L-3,4-dihydroxypheny-
lalanine [levodopa (L-DOPA)] and classical anti-
psychotic drugs’ (APDs) motor side effects
(Bezard et al., 2001; Blackburn, 2004; Di Giovanni
et al., 2006a; Chapters 22 and 23 in this
volume).
During the last decades, advances in the under-
standing of receptors mediating the effect of 5-HT
have represented one of the success stories of
neuropharmacology. Many of the 5-HT receptors
are found within the basal ganglia and most likely
involved in the modulation of basal ganglia
circuitry and in the pathology of their correlated
disorders. Of particular interest with respect to the
development of new treatments for PD and other
motor disorders are the 5-HT1A/1B and 5-HT2A/2C
receptor subtypes. This will be the subject of
further discussion in the remainder of this chapter.
First, the 5-HT innervations of the basal
ganglia and the distribution of 5-HT receptors
throughout the various nuclei will be summarized.
Thereafter, several aspects of 5-HT control of the
pathophysiology of basal ganglia nuclei will be
discussed.
Therefore, it is clear that a detailed under-
standing of the neurotransmitter function in each
condition is not merely academic but can lead to a
rationale for drug design and treatment strategies
appropriate for that group of patients.
5-HT innervation of basal ganglia
More than 50 years have passed since Twarog and
Page (1953) isolated an indole, identiﬁed as 5-HT,
in the mammalian brain. Subsequently, Brodie
et al. (1955) suggested that 5-HT might serve as a
neurotransmitter in the CNS.
In vertebrates, the majority of the neurons contain-
ing 5-HT are grouped in nine nuclei named
B1–B9, located in the medial part of the brain stem,
generically called the raphe nuclei (Dahlstro¨m
and Fuxe, 1964). These midline clusters can
be divided into two major groups. The caudal or
inferior group, localized in the medulla, contains
the three nuclei projecting essentially to the grey
matter of the spinal cord: the nucleus raphe
magnus (NRM, cell group B5), nucleus raphe
obscurus (NRO, cell groups B1, B2 and B3)
and nucleus raphe pallidus (NRP, cell group B4).
The rostral or superior group, located in the
pons/mesenchephalon, contains the dorsal raphe
nucleus (DRN, cell groups B6 and B7) and the
medial raphe nucleus (MRN, cell group B8). These
nuclei supply about 80% of the serotonergic
innervation to the forebrain. Even if, in many
brain areas, the innervation coming from the two
nuclei overlaps, in certain regions, the innervation
comes exclusively or prevalently from one nucleus
only. For example, the dorsal hippocampus
receives a serotonergic innervation only from the
MRN; other areas innervated preferentially from
this nucleus are the medial preoptic area, the
suprachiasmatic nucleus, the olfactory bulb and
the medial septum nucleus. The DRN innervates
all the basal ganglia circuitry (Fig. 1), sending
projections to the corpus striatum, the globus
pallidus (GP), the subthalamic nucleus (STN), the
substantia nigra (SN) and the pedunculopontino
nucleus (PPN), and provides most of the innerva-
tion of the prefrontal cortex, including the
motor cortices. 5-HT-containing cell bodies of the
raphe send projections to both dopaminergic
(DAergic) and gamma-aminobutyric acidergic
(GABAergic) cells in the SN and to their terminal
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ﬁelds (Herve´ et al., 1987; Van Bockstaele et al.,
1993; Moukhles et al., 1997). Moreover, electron
microscopy demonstrates the presence of
synaptic contacts of [3H]5-HT-labelled terminals
with both DAergic and non-DAergic dendrites
in the SN pars compacta (SNc) and reticulata
(SNr) (Herve´ et al., 1987; Moukhles et al.,
1997; Lee et al., 2000). The DRN innervates,
together with the MRN, the ventral part of
the hippocampus, the nucleus accumbens and
various nuclei of the thalamus, among them
the ventral lateral nuclear group that processes
motor information and the hippocampus
(Azmitia and Segal, 1978; Jacobs and Azmitia,
Fig. 1. Basal ganglia motor circuitry in Parkinson’s disease (PD). ‘Motor output’ is used to generalize all descending motor pathways.
During rest, the indirect motor output pathway (GPe-STN-GPi-thalamus) is primarily involved and the direct motor pathway
(GPi-thalamus) is inactive. During periods of activity, the direct motor output pathway is primarily involved. The distribution of
5-HT receptor subtypes in the basal ganglia is indicated based on reports using a variety of methods. Reduced inhibition of the
tonically active STN neurons results in increased inhibition of the thalamus via the pallidothalamic pathway. Intense GPi stimulation
effectively inactivates this structure, reducing the inhibitory inﬂuence upon the thalamus by GPi. Yellow arrow indicates degenerating
nigrostriatal pathway associated with PD; thin lines are pathways with reduced activity; medium-width lines are physiologically
normal pathways; thicker lines are over-active pathways implicated in PD. Proposed sites of action of known 5-HT receptor subtype-
selective compounds associated with PD and L-DOPA-induced dyskinesias are far from clear, but a more detailed understanding of
our present knowledge is given in the main text for each 5-HT therapeutic strategy. SNc, substantia nigra pars compacta; SNr,
substantia nigra pars reticulata; GPi, internal segment of the globus pallidus; GPe, external segment of the globus pallidus; DRN,
dorsal raphe nucleus; STN, subthalamic nucleus; (+) denotes excitatory pathway; and () denotes inhibitory pathway. Adapted with
permission from Blackburn (2004). (See Color Plate 21.1 in color plate section.)
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1992; McQuade and Sharp, 1995). Moreover,
extensive serotonergic connections between the
DRN and the MRN also exist (Jacobs and
Azmitia, 1992).
5-HT receptors’ distribution within the basal
ganglia nuclei
A vast amount of research has led to the discovery
and characterization of a plethora of 5-HT
receptor subtypes. At present, seven classes of
5-HT (5-HT17) receptors have been identiﬁed,
which comprise at least 15 subtypes (Hoyer et al.,
2002) (Table 1). This is not surprising, since with
so many potential targets distributed throughout
the CNS, 5-HT is a major neurotransmitter
involved in such a large number of physiological
and pathological processes.
The distribution of 5-HT receptors among
the various basal ganglia structures has been
widely investigated. Autoradiographic, in situ
hybridization and binding studies, as well as
functional and pharmacological investigations,
showed a differential distribution of the various
5-HT receptor subtypes both within the basal
ganglia nuclei and among the different mammalian
species that were used in these studies (Waeber
et al., 1990a). Strikingly, the described pattern of
distribution and expression of these receptors is
modiﬁed in the animal model of pathologies
involving basal ganglia circuitry as well as in
human patients. Nevertheless, this could be no
more than an epiphenomenal effect.
Striatum
High concentrations of both receptor mRNA and
protein of different 5-HT receptor subtypes have
been found in the striata of various species.
5-HT1A was one of the ﬁrst 5-HT receptor
subtypes that was identiﬁed and pharmacologi-
cally characterized, and its distribution among
different species of mammals has been widely
investigated. So far, most of the receptor auto-
radiography, radioimmunohistochemistry and in
Table 1. Serotonin receptor subtypes
Receptor Type of
receptor
Effector
mechanisms
Subtypes Location in the basal ganglia Speculated function
5-HT1 G protein
linked
Inhibits adenylyl
cyclase, opens
K+ channels
5-HT1A Caudate-putamen, subthalamic nucleus Anxiety, depression
5-HT1B Caudate-putamen, substantia nigra, globus
pallidus
Locomotion
5-HT1D Substantia nigra Locomotion
5-HT1E Caudate-putamen
5-HT1F Caudate-putamen
5-HT2 G protein
linked
Stimulation of
phospholipase C,
closing of K+
channels
5-HT2A Nucleus accumbens, caudate-putamen
5-HT2B None detected in the basal ganglia
5-HT2C Nucleus accumbens, caudate-putamen,
substantia nigra, subthalamus
5-HT3 Ligand-gated
cation
channel
Na+ current 5-HT3A,
5-HT3B,
5-HT3C
GABAergic projection neurons of
caudate-putamen
Anxiety, depression,
emesis
5-HT4 G protein
linked
Stimulation of
adenylyl cyclase
5-HT4 GABAergic projection neurons of
caudate-putamen
Anxiety, depression
5-HT5 G protein
linked
Inhibits adenylyl
cyclase
5-HT5A,
5-HT5B
Caudate-putamen Motor control, feeding,
anxiety, depression,
learning, memory
5-HT6 G protein
linked
Stimulation of
adenylyl cyclase
5-HT6 Dendrites of GABAergic striatopallidal and
striatonigral neurons
Dopamine transmission
5-HT7 G protein
linked
Stimulation of
adenylyl cyclase
5-HT7 Caudate-putamen, nucleus accumbens Locomotion, circadian
rhythms
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situ hybridization studies have reported low or
barely detectable levels of labelling for both
5-HT1A receptor protein and mRNA in the
caudate-putamen of the rat (Miquel et al., 1991;
Riad et al., 1991; Kung et al., 1995; Wright et al.,
1995), mouse (Schiller et al., 2003) and primate
brain (Mengod et al., 1996). The same regional
distribution has been found in the caudate and
putamen nuclei of human brain, using postmortem
radiolabelling and in vivo positron emission
tomography (PET) with various radiotracers (Pike
et al., 1995; Pasqualetti et al., 1996; Hall et al.,
1997; Duncan et al., 1998; Ito et al., 1999).
However, a recent study reported a patchy
distribution of 5-HT1A receptors conﬁned to
striosomes of the primate striatum characterized
by poor calbindin immunostaining. In these
compartments, the receptor density was equal to
that in other enriched brain areas, such as some
hippocampal ﬁelds, and it was increased in a
1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP)-lesioned primate model of PD, suggesting
a key role for this receptor subtype in the control
of movement by the basal ganglia (Frechilla et al.,
2001).
The 5-HT1B receptor subtype localization in the
striatum has been widely demonstrated in various
mammal brains. In rats and mice, early [3H]5-HT
binding studies, using selective ligands as displa-
cing agents for the 5-HT1A receptor subtype,
showed intermediate-to-low concentrations of
5-HT1B binding or immunoreactivity sites in
the caudate-putamen (Pazos and Palacios,
1985; Blurton and Wood, 1986; Verge et al., 1986;
Waeber et al., 1989; Middlemiss and Hutson, 1990;
Sari et al., 1999). In a ﬁrst attempt to characterize
the distribution of 5-HT receptors in the brains of
different mammal species, autoradiographic data
seemed to indicate a lack, in cats, guinea pigs,
monkeys and humans, of receptors with a phar-
macological proﬁle similar to that of the rat and
mouse 5-HT1B (Hoyer et al., 1986; Pazos et al.,
1987a; Waeber et al., 1989). Similarities in the
5-HT1D distribution in the brains of these species
to that of 5-HT1B in rats and mice led to the
hypothesis that these two receptor subtypes were
species homologues (Waeber et al., 1989; del Arco
et al., 1993). Subsequent ﬁndings, relative to the
molecular cloning of 5-HT1 receptor subtypes,
showed the presence, in human brain, of two genes
expressing different receptors displaying the
pharmacology of the originally described 5-HT1D
sites, named 5-HT1Da and 5-HT1Db (77% sequence
homology in the transmembrane domain).
5-HT1Db showed a 96% homology to the cloned
rodent 5-HT1B receptor. Following this new
experimental evidence, the 5-HT1B/1D receptor
nomenclature underwent a reassessment (for
reviews, see Barnes and Sharp, 1999; Hoyer
et al., 2002). According to the new classiﬁcation,
comparative studies showed binding sites for this
receptor, as well as high hybridization signals for
its mRNA, in the caudate-putamen of rodent brain
(Bruinvels et al., 1994; Bonaventure et al., 1998)
and the corresponding caudate and putamen in
humans (Varnas et al., 2001, 2005); moreover,
some authors showed a dorsoventral gradient in
the distribution of both this receptor and its
mRNA, with higher levels in the ventral as
compared to the dorsal striatum (Compan et al.,
1998; Varnas et al., 2001, 2005) in both rats and
humans. According to the authors, this evidence,
together with the complete lack of mRNA in both
the SN and ventral pallidum, seems to indicate a
localization of the 5-HT1B receptor subtype on
axon terminals arising from medium spiny neurons
(MSNs) of the ventral striatal regions, thus
conﬁrming previous immunoreactivity and in situ
hybridization studies in mouse and rat brain
(Boschert et al., 1994; Sari et al., 1999). On the
other hand, binding sites in the striatum may
reﬂect both somatodendritic and presynaptic
localizations of this receptor on striatal neurons
(projection neurons and/or interneurons) or on
thalamic/cortical afferents, respectively (Bonaventure
et al., 1998).
The presence of 5-HT1D (namely, 5-HT1Da)
receptor and mRNA in the striatum of rodents,
primates and humans has been reported, even if
weaker levels of both protein-binding and hybri-
dization signals were observed with respect to the
5-HT1B (Bruinvels et al., 1993a). Similarly to
5-HT1B receptors, some authors described a
discrepancy in the distribution pattern of 5-HT1D
mRNA and its protein in the striatum, SN and GP
of mouse brain and therefore hypothesized a
427
Author's personal copy
presynaptic localization of 5-HT1D receptors in the
latter two areas (Boschert et al., 1994). Finally,
regarding the 5-HT1 receptor family, Bruinvels et
al. (1993b) reported the presence of the 5-HT1E
receptor subtype mRNA in both the caudate
nucleus and putamen of primates, showing stron-
ger hybridization signals in monkey brain than
that obtained in human brain.
Both 5-HT2A receptor subtype and its mRNA
have been extensively demonstrated to be present
in the striatum of various mammal species. More-
over, the described distribution pattern showed
increasing gradients for this receptor in the
rostrocaudal and mediolateral directions
(Pazos et al., 1985, 1987b; Mengod et al., 1990;
Pompeiano et al., 1994; Wright et al., 1995; Lopez-
Gimenez et al., 1997). In human brain, using
the high-afﬁnity radioligand [3H]MDL 100907, a
high density of labelling has been shown to be
distributed in patches throughout the caudate
nucleus and putamen (Lopez-Gimenez et al.,
1999). Regarding cellular distribution, the 5-HT2A
receptors showed a somatodendritic localization,
as demonstrated also by the correlation between
the distribution of 5-HT2A protein and its mRNA
(Cornea-He´bert et al., 1999). Furthermore, a more
prominent localization in dendrites than in cell
bodies was found in the dorsolateral caudate-
putamen of rat brain, using immunocytochemistry
(Rodrı´guez et al., 1999).
A number of studies have demonstrated a
widespread distribution of the 5-HT2C receptor
subtype in rat, monkey and human brains,
particularly among the different basal ganglia
structures. Moreover, marked differences have
been revealed in the distribution of 5-HT2C
mRNA and its level of expression within the
different subregions of the basal ganglia (Hoffman
and Mezey, 1989; Mengod et al., 1990; Wright
et al., 1995; Eberle-Wang et al., 1997). Most
labelled neurons in the striatum were efferent
medium-sized neurons but not cholinergic inter-
neurons, although recent polymerase chain reac-
tion (PCR) evidence instead revealed high
expression of 5-HT2C, 5-HT6 and 5-HT7 mRNAs
in cholinergic interneurons (Bonsi et al., 2007a).
Neurons expressing 5-HT2C mRNA have been
found in discrete areas of the caudate-putamen
showing no preferential localization with sub-
stance P, dynorphin or enkephalin, thus indicating
that 5-HT2C receptors are not differentially
expressed on the two major striatal output path-
ways (striatonigral and striatopallidal projection
neurons). On the other hand, with regard to patch/
matrix striatal structures, 5-HT2C mRNA showed
a preferential localization in the patch compart-
ment areas, suggesting a role for this receptor in
the modulation of striatal projections to the SNc
(Gerfen, 1984, 1985; Ward and Dorsa, 1996).
Using various radioligands, some authors have
reported the presence of 5-HT3 receptors in the
striatum of different mammals, albeit higher
receptor densities have been found in the human
caudate nucleus and putamen than in the corre-
sponding structures of the rat brain (Barnes et al.,
1990; Gehlert et al., 1991; Laporte et al., 1992;
Abi-Dargham et al., 1993; Bufton et al., 1993;
Parker et al., 1996; Morales et al., 1998; Fletcher
and Barnes, 1999; Marazziti et al., 2001). Binding
studies on homogenates of human putamen
suggested a localization of these receptors on
neurons that have their cell bodies within this
region, such as GABAergic projection neurons,
but not on DAergic neurons. Indeed, patients with
diagnosed Huntington’s disease showed decreased
binding densities in the striatum, unlike those
affected by DAergic cell loss associated with PD
(Steward et al., 1993). Moreover, as for other brain
areas, data obtained using synaptosomes isolated
from rat striatum showed the presence in this area
of functional presynaptic 5-HT3 receptors, besides
the known postsynaptic localization (Nichols and
Mollard, 1996; Ronde and Nichols, 1998; Nayak
et al., 1999).
An analysis of the distribution of the 5-HT4
receptor showed its presence in several compo-
nents of the basal ganglia of different mammal
species. Generally, the distribution pattern of the
5-HT4 receptor binding sites in the striatum
matched that observed for its mRNA in all the
different species used in binding and in situ
hybridization studies. However, some species’
differences have been shown. Thus, ventrome-
dial-to-dorsolateral-increasing gradients of label-
ling densities have been observed in the rat and
mouse brain caudate-putamen (Waeber et al.,
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1994; Vilaro et al., 1996), while it was less
pronounced in the same structure of guinea pig
brain; similarly, monkey and human caudate
nuclei and putamens showed very high densities
of receptor and mRNA binding sites but no
apparent gradient in their distribution (Bonaventure
et al., 2000; Vilaro et al., 2005). The decrease in
binding densities following selective lesion of
rat caudate-putamen indicated a somatodendritic
localization of 5-HT4 receptors on GABAergic
projection neurons and cholinergic/GABAergic
interneurons in this structure; on the other hand,
following 6-hydroxydopamine (6-OHDA) lesion
of the nigrostriatal pathway, there were no
changes in striatal levels of receptor binding,
clearly indicating that this receptor was not
localized on DAergic terminals (Compan et al.,
1996; Vilaro et al., 2005). These data are in
agreement with postmortem studies on brains of
patients with Huntington’s disease or PD, showing
a decrease in receptor binding only in the ﬁrst
group of patients (Reynolds et al., 1995; Vilaro
et al., 2005).
Only moderate-to-low expression of 5-HT5A
receptor protein and mRNA has been found in
the striatum of mouse, rat and human brain (Boess
and Martin, 1994; Rees et al., 1994; Wesolowska,
2002). In particular, 5-HT5A immunoreactivity
was detectable at low levels in MSNs of rat
caudate-putamen (Oliver et al., 2000).
On the other hand, the 5-HT6 receptor subtype
has been shown to be particularly abundant in this
area of the basal ganglia. High levels of both
protein and mRNA expression have been found
in the caudate-putamen of rat and pig brain
(Monsma et al., 1993; Ruat et al., 1993a; Ward
et al., 1995; Kohen et al., 1996; Yoshioka et al.,
1998; Hirst et al., 2000) as well as in the caudate
nucleus and putamen of human brain (Kohen
et al., 1996; Hirst et al., 2003), thus demonstrating
a similar distribution pattern for this receptor in
the brains of these species. In contrast, only low
levels of both 5-HT6 receptor protein and mRNA
have been found in the same brain areas of two
different strains of mice (Hirst et al., 2003). As the
regional distribution of 5-HT6 receptor generally
matched that found for the 5-HT6 receptor
mRNA, it is likely that the former is mainly
localized on somas and/or dendrites of neurons.
This conclusion is further supported by light and
electron microscopy immunoreactivity data clearly
showing the localization of this receptor on
dendritic processes of spiny neurons in the
striatum (Gerard et al., 1997; Hamon et al.,
1999). Finally, selective lesion of 5-HT neurons
by injection of 5,7-dihydroxytryptamine (5,7-
DHT) in the DRN has been shown to not
affect the levels of 5-HT6 mRNA in the striatum
of rat brain, thus conﬁrming the postsynaptic
localization of this receptor with respect to 5-HT
neurons innervating this area (Gerard et al.,
1996). Similarly, the lack of any difference in
the levels of protein binding, following 6-OHDA
selective lesion of the nigrostriatal pathway,
demonstrates that the 5-HT6 is also not located
on membranes of DA neurons (Roberts et al.,
2002).
Finally, the presence of the 5-HT7 receptor
subtype has been reported in the striatum of
rodents as well as in the caudate nucleus and
putamen of human brain, with a protein distribu-
tion pattern generally matching that of its
mRNA. In addition, some species’ differences in
receptor densities were reported between human
and rodent brain (Ruat et al., 1993b; Wesolowska,
2002; Martin-Cora and Pazos, 2004; Varnas et al.,
2004).
Substantia nigra and globus pallidus
Very low levels of binding have been found in the
SN or the GP of mouse, rat and human brains for
both 5-HT1A receptor protein and its mRNA
(Khawaja, 1995; Kung et al., 1995; Wright et al.,
1995; Hall et al., 1997; Schiller et al., 2003).
Interestingly, some authors showed high binding
of [3H]zolpidem in the rat SN in contrast to low
binding observed in the same region of human
brain (Duncan et al., 1998). By contrast, among
the basal ganglia nuclei, the highest levels of
5-HT1B protein bindings were found in both the
SN and the GP of different mammal species.
Unlike the striatum, in situ hybridization studies
failed to reveal the presence of 5-HT1B mRNA in
these structures. Taken together, therefore, these
data seem to suggest a presynaptic localization of
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this receptor subtype, presumably on terminals of
striatal afferents (Pazos et al., 1987a; Boschert
et al., 1994; Bruinvels et al., 1994; Bonaventure
et al., 1998; Sari et al., 1999; Varnas et al., 2001,
2005), where it acts as heteroreceptor (Barnes and
Sharp, 1999). Moreover, the levels of 5-HT1B
binding sites in these areas after selective lesion of
nigral DAergic cells or striatal neurons, as well as
radioligand studies on postmortem human brain
of patients who had suffered degenerative move-
ment disorders, clearly demonstrate the localiza-
tion of this receptor on striatonigral and
striatopallidal GABAergic afferents (Waeber
et al., 1990b; Castro et al., 1998; Compan et al.,
1998). Similarly to the 5-HT1B subtype, radiola-
belled sites for 5-HT1D receptors were found in
these structures, despite the lower densities as
compared to the previous receptor (partially due
to the lack of speciﬁc radioligand), while in situ
hybridization studies showed a lack of its mRNA
(Bruinvels et al., 1993a, 1994). Again, these data,
together with receptor and mRNA distribution
in the striatum previously reported, are in line
with a putative localization on axon terminals in
these areas.
Regarding the 5-HT2 family, intermediate levels
of 5-HT2A receptor mRNA were found in the SNc,
SNr and pars lateralis of rat brain (Mengod et al.,
1990; Pompeiano et al., 1994; Wright et al., 1995).
Regarding receptor distribution, as mentioned
above, there is a general concordance between the
distributions of 5-HT2A protein and its mRNA.
Early studies found high concentrations of
[3H]ketanserin binding in the SNc and the SNr in
rats while only very low concentrations of this
receptor have been shown in the GP (Pazos et al.,
1985, 1987b). Nevertheless, some recent immuno-
histochemistry and autoradiography studies found
lower levels of 5-HT2A receptors expressed in these
areas (Cornea-He´bert et al., 1999; Lopez-Gimenez
et al., 1999; Bubser et al., 2001). These discrepan-
cies in receptor concentrations in the SN could be
explained by the use in previous studies of some
radioligands, such as [3H]ketanserin, which has
been shown to have a high afﬁnity for non-
serotonergic sites, as well as its known selectivity
for the 5-HT2 receptor family (Lopez-Gimenez et
al., 1997). Finally, the presence of this receptor
subtype in the GP of rat brain has been conﬁrmed
by recent immunohistochemistry data showing
that about 70% of neurons expressing the 5-HT2A
receptor project to the striatum (Bubser et al.,
2001). Neither 5-HT2C mRNA nor receptor
protein has been found in the GP or in the
entopeduncular nucleus (EPN) while neurons
showing labelling for this receptor have been
found in both the SNc and the SNr. Furthermore,
the distribution pattern of 5-HT2C in this area
showed a marked rostrocaudal labelling gradient,
characterized by higher receptor densities in
caudal regions of both nuclear subdivisions.
Finally, with regard to cellular localization,
receptor expression seems to be conﬁned to
GABAergic neurons but not to DAergic cell
bodies (Van Bockstaele et al., 1994; Van Bockstaele
and Pickel, 1995; Steffensen et al., 1998; Di
Giovanni et al., 2001).
The 5-HT3 receptor subtype has been detected
by membrane binding essays and immunolabelling
in the SN of both rat and human brain (Laporte
et al., 1992; Bufton et al., 1993; Gehlert et al.,
1993; Doucet et al., 1999). Nevertheless, only
lightly detectable receptor densities have been
shown for this area.
The presence of 5-HT4 receptor protein, but not
its mRNA, has been reported in both the GP and
the SN of different mammal species, with the
highest densities in the latter area, thus supporting
the idea of a localization of this receptor
on striatopallidal and striatonigral terminals
(Compan et al., 1996; Ullmer et al., 1996; Vilaro
et al., 1996; Bonaventure et al., 2000). Moreover,
5-HT4 receptor binding sites in the rat SN were
conﬁned to the pars lateralis, while in guinea
pig brain, a wider distribution was observed
in the same area, with most of the SNr being
strongly labelled (Waeber et al., 1994; Vilaro
et al., 2005); in human and monkey brain, the
distribution pattern resembled that of guinea pig
brain.
Finally, with regards to the last three 5-HT
receptor families, only moderate-to-low concen-
trations of both receptor proteins and mRNA
have been found in the SN and the GP of rat and
human brain for the 5-HT5A (Rees et al., 1994;
Oliver et al., 2000), 5-HT6 (Kohen et al., 1996;
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Gerard et al., 1997; Hamon et al., 1999; Roberts
et al., 2002; Hirst et al., 2003) and 5-HT7 (Ruat
et al., 1993b; Martin-Cora and Pazos, 2004;
Varnas et al., 2004) receptor subtypes.
Subthalamic nucleus
So far, little evidence exists regarding the presence
of moderate-to-low concentrations of 5-HT1A,
5-HT4, 5-HT5 and 5-HT6 receptors and/or their
mRNA in the STN (Pompeiano et al., 1992). By
contrast, high hybridization signals were found for
both 5-HT1B and 5-HT2C receptor mRNAs in the
rodent brain (Bruinvels et al., 1994; Eberle-Wang
et al., 1997).
5-HT modulation of basal ganglia circuitry
The 5-HT modulation of DAergic nigrostriatal
function, in terms of control of DA SNc neuron
ﬁring discharge and DA release in the striatum,
has been extensively reviewed in Chapters 2 and 3.
Therefore, we will not discuss this subject and we
refer the readers to these two chapters.
5-HT modulation of striatal activity
In agreement with anatomical data, most of the
reports on this subject indicate that striatal cells
are predominantly affected by dorsal raphe (DR)
stimulation, with the median raphe stimulation
being unable to alter striatal cell activity directly
(Olpe and Koella, 1977; Davies and Tongroach,
1978). In addition, it has been found that
suppression of spontaneous ﬁring activity is the
main response of cultured striatal cells (Yakel
et al., 1988) in vivo following DRN stimulation,
and excitation being observed in only about 10%
of them. Nevertheless, a rebound excitation was
observed in some cells that were initially inhibited.
Local application of 5-HT was found to produce
changes similar to that caused by raphe stimula-
tion, and most of the cells responsive to the raphe
stimulation were also affected by nigral stimula-
tion (Davies and Tongroach, 1978). However,
using intracellular recording techniques, Kitai and
co-workers (Vandermaelen et al., 1979) found that
DRN stimulation was consistently capable of
generating excitatory postsynaptic potentials.
These ﬁndings were subsequently repeated in the
laboratory by the authors, and it was indicated
that non-5-HT DRN-striatal neurons could be
involved in striatal responses to 5-HT. They also
showed that the increase of the ﬁring frequency in
rat neostriatal MSNs induced by 5-HT depended
on reducing voltage-dependent potassium currents
(Park et al., 1982; Stefani et al., 1990; Wilms et al.,
2001).
Stimulation of postsynaptic 5-HT1A recep-
tors by 8-hydroxy-2-(di-n-propylamino)tetralin
(8-OHDPAT) induced an increase in locomotor
activity (Mignon and Wolf, 2002). Moreover,
Gerber et al. (1988) and Matsubara et al. (2006)
reported that 5-HT1A receptor stimulation has an
anti-parkinsonian effect in 6-OHDA-lesioned rats,
inducing a robust contralateral rotational beha-
viour. Current theories of circling behaviour
hypothesize that the animal turns away from the
basal ganglia output, where activity has been
reduced. Moreover, the stimulation of 5-HT1A
receptors has been shown to be capable of
inducing contralateral rotation also following
degeneration of the DRN (Blackburn et al.,
1984; Gerber et al., 1988). This rotational beha-
viour has been explained by a supersensitivity of
5-HT1A receptors in the SNc of the DA-lesioned
rats, resulting in an increase of DA in the striatum
(Blackburn et al., 1984; Gerber et al., 1988). In
agreement with this theory, tandospirone, a highly
potent and selective 5-HT1A receptor agonist,
remarkably potentiated the contralateral turning
induced by apomorphine (Matsubara et al., 2006).
Nevertheless, it has been shown that 8-OHDPAT
can also induce ipsilateral turning in unilateral
6-OHDA-lesioned rats (Mignon and Wolf, 2002,
2007).
The discrepancies notwithstanding these ﬁnd-
ings are valuable in demonstrating the potential
utility of drugs that possess 5-HT1A in the
symptomatic treatment of PD. The 5-HT1A
agonists might inhibit 5-HT release, acting pre-
synaptically (Gerber et al., 1988), or have a
postsynaptic action (Lucas et al., 1997; Matsubara
et al., 2006), decreasing striatal glutamate release
from corticofugal projections, without involving
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direct activation of D2 receptors (Antonelli et al.,
2005; Mignon and Wolf, 2005, 2007). Similarly,
WAY 100135 increased glutamate (GLU) outﬂow
in the striatum of rats (Dijk et al., 1995). These
ﬁndings suggest that 5-HT1A receptor stimulation
could give rise to a decrease in the corticofugal
glutamate drive (e.g. to the striatum or the STN)
that could ultimately be manifested as decreased
activation of the output nuclei of the basal
ganglia (medial GPi and SNr). A reduction in
excitatory drive to these output nuclei would
lead to a disinhibition of the motor thalamus,
thereby ameliorating the motor deﬁcits of PD
(Mignon and Wolf, 2007). These results suggest
that 5-HT1A agonists could have therapeutic
potentials for the treatment of PD by modulating
neuronal activities of non-DAergic pathways,
such as the excitatory amino acid pathways in the
basal ganglia.
5-HT released from serotonergic terminals in the
striatum exerts a negative feedback on its own
neuronal activity via 5-HT1B as well as 5-HT1A
autoreceptors. Indeed, stimulation of 5-HT1B
receptors, localized on the terminals of 5-HT
neurons, reduced 5-HT release and also modulated
L-DOPA metabolism to DA in the striatum
(Knobelman et al., 2000; Carta et al., 2007).
Several in vivo electrophysiological and neuro-
chemical studies suggest an important role of the
5-HT1B receptor in modulating the activity of
mesostriatal DAergic neurons. Indeed, 5-HT1B
receptor stimulation enhances striatal DAergic
activity, generally attributed to an inhibition of
GABA release and a consequent disinhibition of
DA neuronal activity (see Chapters 2 and 3). Rats
with unilateral DRN lesions showed contralateral
turning in response to the putative 5HT1B agonist
RU 24969, while a much weaker effect was
revealed in 6-OHDA-lesioned rats (Gerber et al.,
1988). 5-HT1A and 5-HT1B receptors appear to act
synergistically in reducing 5-HT transmission in
the basal ganglia, and it is important to note that
low doses of agonists for these receptors are able
to suppress dyskinesia, without affecting the anti-
parkinsonian effect of L-DOPA in the presence
of spared DA terminals, suggesting an early use of
these drugs to counteract the development of
dyskinesia in PD patients (see Chapter 22).
The 5-HT2 family has been intensively investi-
gated in the striatum. Compelling data by Blier
and colleagues (el Mansari et al., 1994; el Mansari
and Blier, 1997) concerning single-unit recordings
coupled with microiontophoresis in vivo, in rats,
guinea pigs and 5-HT2C receptor mutant mice,
support the hypothesis of an inhibitory action
of the 5-HT system on the neuronal activity of
the striatum [presumably MSNs] that through the
activation of 5-HT2 receptors. These authors
investigated only in the head of the caudate
nucleus and reported an inhibitory effect of
5-HT, mimicked by the 5-HT2A receptor agonist
1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane
(DOI) and the 5-HT2C receptor agonist m-chloro-
phenylpiperazine (mCPP) (el Mansari et al.,
1994; el Mansari and Blier, 1997). It is noteworthy
that signiﬁcantly less quisqualate was required to
activate neurons in the caudate nucleus of 5-HT2
mutant mice than in the wild-type mice, suggesting
that 5-HT2C receptors serve a tonic inhibitory role
in membrane excitability (Rueter et al., 2000).
Strikingly, neither the selective 5-HT2A agonist
MDL 100907 nor clozapine antagonized DOI or
mCPP in the caudate nucleus in mice. The authors
suggested that DOI and mCPP might be acting in
the caudate nucleus through an atypical 5-HT2
receptor yet to be characterized and a hypothesis
that has not been investigated by successive
studies. More likely, this lack of antagonism
depends on the pharmacological design of the
experiments. Indeed, in rats, el Mansari and Blier
(1997) showed that the inhibitory effect of DOI,
but not that of mCPP, was antagonized by a
4-day treatment with metergoline and ritanserin,
indicating that the suppressant effect of DOI
may be mediated by 5-HT2A receptors in the
head of the caudate nucleus. Contrary evidence
has been shown by an in vivo study in which
only excitation of the striatal neurons induced
by microiontophoretical application of 5-HT
was revealed, while DOI caused a preferential
inhibitory response, highlighting diverse effects
of 5-HT in different parts of the striatum (Wilms
et al., 2001).
Recently, the role of serotonergic control on
striatal cholinergic interneurons has been explored
in vitro (Blomeley and Bracci, 2005; Bonsi et al.,
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2007a). Striatal acetylcholine (ACh), and its inter-
play with DA, has long been recognized as playing
a crucial role in voluntary movement (Duvoisin,
1967). In the striatum, ACh is mainly released by a
population of large aspiny interneurons (LAIs)
(Phelps et al., 1985; Zhou et al., 2002; Tepper and
Bolam, 2004). Pakhotin and Bracci (2007) have
shown that LAIs exerted a strong inhibitory
control over the neighbouring striatal MSNs
via inhibition of their GLUergic input. These
effects are presynaptic and mediated by both
M2 and M3 muscarinic receptors, both present
on corticostriatal terminals. 5-HT strongly and
reversibly increased spontaneous ﬁring rates of
LAIs in vitro via a reversible reduction of two
pharmacologically and kinetically distinct after-
hyperpolarizations (AHPs) that play an important
role in limiting the excitability of cholinergic
interneurons (Blomeley and Bracci, 2005).
Blomeley and Bracci (2005), furthermore, showed
that 5-HT2 receptors were responsible for the
excitatory effects of 5-HT in cholinergic interneu-
rons, although they could not identify the 5-HT
receptor subtype involved since they used
a-methyl-5-HT and ketanserin, highly unspeciﬁc
ligands. Recently, Bonsi et al. (2007a) managed to
rule out the role of 5-HT2A showing that only the
pretreatment with the selective 5-HT2C antagonist
RS 102221 caused a signiﬁcant reduction in the
5-HT-induced depolarization of cholinergic inter-
neurons. This evidence was strongly supported by
PCR analysis data showing that the 5-HT2C
receptors are expressed by about 80% of LAIs in
contrast to a sporadic expression of the 5-HT2A
subtypes. Accordingly, the response of striatal
cholinergic interneurons to the 5-HT was partially
blocked by phospholipase C (PLC) inhibitor, the
transduction pathways linked to the 5-HT2C
receptor subtypes. Thus, 5-HT induces cell depo-
larization and increase in ﬁring frequency, acting
through postsynaptic 5-HT2C receptors, probably
causing inhibition of K+ currents or increase of a
cationic conductance in striatal cholinergic inter-
neurons. In the light of these recent results,
5-HT2C agonists might reduce striatal MSN
activity indirectly via an increase of the inhibitory
cholinergic tone. Moreover, 5-HT6 and 5-HT7
receptor subtypes are also involved in the potent
excitatory effect of 5-HT but not in that of 5-HT3
and 5-HT4 (Bonsi et al., 2007a). Therefore,
modulating the activity of cholinergic striatal
interneurons by 5-HT2C, 5-HT6 or 5-HT7 recep-
tors may have positive therapeutic beneﬁts for
motor diseases.
In concordance with these inhibitory 5-HT
effects on MSNs through the activation of 5-HT2C
receptors, there is the behavioural evidence that
caudate injections of 5-HT provoked contraversive
turning, while conversely, intracaudate methyser-
gide induced ipsiversive circling (James and Starr,
1980). In addition, the facilitation by hyoscine and
the attenuation by eserine of the 5-HT-induced
contraversive circling, together with the converse
effects of these drugs on methysergide-evoked
ipsiversive rotations, are consistent with raphe–
caudate 5-HT ﬁbres synapsing directly with, and
exciting, striatal cholinergic neurons. Given that
motor behaviour recruits multiple striatal neuro-
transmitter systems, recent attention has focused
on the interaction between DA and 5-HT recep-
tors. In the intact striatum, several studies have
consistently demonstrated that intrinsic 5-HT2
receptors can modify DA function and have
postulated divergent roles for 5-HT2A and 5-HT2C
receptor subtypes (Lucas et al., 2000; Porras et al.,
2002). 5-HT2A antagonists reduce hyperlocomo-
tion induced by cocaine, amphetamine and
3,4-methylenedioxymethyamphetamine (MDMA)
(Kehne et al., 1996; O’Neill et al., 1999), whereas
5-HT2C receptor antagonists have been shown to
enhance or reduce these effects, depending upon
the compounds and neuronal sites studied (Filip
and Cunningham, 2002; Fletcher et al., 2002; Filip
et al., 2004). Recent studies by Walker’s group
have shown that, following DA depletion,
D1-induced locomotor activity can be reduced by
antagonism of striatal 5-HT2A, but not 5-HT2C,
receptors (Bishop et al., 2005). This preferential
involvement of the 5-HT2A subtype is conﬁrmed
by the evidence that intrastriatal injections of the
selective 5-HT2C antagonist RS 102221 had no
effect on motor activity; conversely, the 5-HT2A
agonist DOI induced motor behaviour in neonatal
6-OHDA-lesioned rats, which was attenuated by
the 5-HT2A receptor antagonism (Bishop et al.,
2004).
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Interestingly, recent pharmacological data and
lesion studies have established that the biosynth-
esis of neuropeptides in the striatum is regulated
by the 5-HT innervation originating from the
DRN, suggesting that 5-HT in the striatum might
exert a metabolic regulatory function on the
biosynthesis of neuropeptides rather than acting
as an ion channel modulator (Horner et al., 2005;
D’Addario et al., 2007).
5-HT modulation of SNr activity
The SNr neurons receive the largest 5-HT innerva-
tion from the DRN of all brain regions (Fibiger
and Miller, 1977; Corvaja et al., 1993) and express
a high level of 5-HT receptors, which are both
postsynaptic and located on the somatodendritic
region of SNr neurons and postsynaptic on
terminals of SNr inputs. It has been calculated
that the density of 5-HT-immunoreactive varico-
sities in the SNr is in the order of 9 106/mm3, of
which about 74% form synaptic specializations
with GABAergic projection neurons (Moukhles
et al., 1997). This picture gives an idea of the great
inﬂuence that 5-HT could have on the activity
of SNr neurons. Early studies have revealed a
primarily inhibitory action of 5-HT on SNr
neurons. Electrical stimulation of the DRN caused
mostly inhibitory responses in the SNr, as mea-
sured by single-unit extracellular recordings in
vivo (Fibiger and Miller, 1977). Similarly, the
iontophoresis of 5-HT into the SN produced
mixed, although mostly inhibitory, effects in the
SNr (Dray et al., 1976; Collingridge and Davies,
1981). The inhibition of SNr neurons by 5-HT is
supported by the ﬁnding that unilateral injection
of 5-HT, 5-HT1D agonist and selective serotonin
reuptake inhibitors (SSRIs) into the SNr of freely
moving rats elicited a contraversive circling
behaviour (James and Starr, 1980; Blackburn
et al., 1981; Oberlander et al., 1981; Higgins
et al., 1991; Bata-Garcia et al., 2002) as muscimol
does (Oberlander et al., 1981). In spite of this
evidence, Lacey and co-workers have shown, by
using in vitro electrophysiological methods, that
5-HT not only directly excites SNr neurons but
also disinhibits them by reducing GABA release
from striatonigral terminals, acting on presynaptic
5-HT1B receptors (Rick et al., 1995; Stanford and
Lacey, 1996). On the other hand, a subsequent
electrophysiological in vitro study demonstrated
also a direct inhibitory action of 5-HT on SNr
neurons (Gongora-Alfaro et al., 1997). 5-HT and
the 5-HT-uptake inhibitor duloxetine reduced the
ﬁring rate of the majority of SNr neurons
recorded, suggesting that synaptically released
endogenous 5-HT act directly on 5-HT1B receptors
located in these neurons. The agonists that
mimicked that effect were only of the 5-HT1B
class (CP 93129 and TFMPP). Neither the 5-HT2
antagonist ritanserin nor the GABAA antagonist
bicuculline were able to block that inhibition,
suggesting that, in addition to an indirect action
(Stanford and Lacey, 1996), some SNr neurons
may be directly inhibited by 5-HT.
The 5-HT-induced excitation observed in the
majority of the SNr neurons recorded is most
probably mediated by a direct action on 5-HT2
receptors being blocked by ketanserin and ritan-
serin and mimicked by a-methyl-5-HT, unselective
antagonists and agonists of the 5-HT2 receptor
subtype (Rick et al., 1995; Stanford and Lacey,
1996). In addition, Gongora-Alfaro and collea-
gues’ in vitro study revealed that 5-HT could excite
about half of the SNr neurons tested; this effect
was seen in the neurons blocked by methysergide,
thus conﬁrming the involvement of 5-HT2 recep-
tors (Gongora-Alfaro et al., 1997). The above
experimental evidence, although underlining a
pivotal role for the 5-HT2 receptor subtype in the
modulation of SNr neurons, does not discriminate
the involvement of different subtypes. We have
tried to answer this question, and consistent with
the aforementioned evidence, we showed that
selective 5-HT2C activation excites SNr neurons
in vivo (Di Giovanni et al., 2001; Invernizzi et al.,
2007). This effect was evident after both systemic
administration and local microiontophoretic appli-
cation of mCPP and Ro 60-0175 (Di Giovanni
et al., 2001; Invernizzi et al., 2007). As further
conﬁrmation of a selective activation of 5-HT2C
receptors, excitatory effects of mCPP and Ro
60-0175 were blocked by pretretment with SB
242084 and SB 243213, potent and selective
5-HT2C antagonists. An interesting ﬁnding of our
ﬁrst study was the differential effect exerted by
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mCPP on subpopulations of SNr neurons. Thus,
mCPP caused a marked excitation of the so-called
P(0) non-DA neurons in the SNr, whereas it did
not affect the P(+) neurons. These neurons are
identiﬁed on the basis of the presence P(+) or the
absence P(0) of an excitatory response to a noxious
stimulus (footpinch). There is evidence that P(+)
neurons in the SNr are GABAergic interneurons
that exert a direct inhibitory inﬂuence on DA
neurons in the SNc, whereas P(0) cells represent
SNr projection neurons. Thus, mCPP caused a
marked excitation of presumed SNr projection
neurons but did not modify the SNr interneuron
ﬁring discharge (Di Giovanni et al., 2001). These
data have been conﬁrmed using Ro 60-0175, the
most selective agonist to date, which caused
excitation only in half of the SNr neurons
recorded, although no information about the
territory of their innervations was investigated
(Invernizzi et al., 2007). Nevertheless, it is most
likely that the SNr neurons excited by the 5-HT2C
agonist Ro 60-0175 are the P(0)-projecting neu-
rons that responded to mCPP treatment (Di
Giovanni et al., 2001). Consistent with these
electrophysiological data, both systemic and intra-
nigral administration of Ro 60-0175 and mCPP
markedly increased extracellular GABA levels in
the SNr, while glutamate levels were not affected.
The stimulatory effect of systemic and local Ro
60-0175 on GABA release was dependent on the
ongoing neuronal activity [tetrodotoxin (TTX)
sensitive] and completely prevented by systemic
administration of SB 243213. On the other hand,
local application of SB 243213 into the SNr only
partially blocked Ro 60-0175-induced GABA
release. This suggests that the control exerted by
5-HT2C receptors on extracellular GABA in the
SNr involves both intra- and extranigral compo-
nents, such as the striatonigral pathway (Invernizzi
et al., 2007). Based on our in vivo (Di Giovanni
et al., 2001; Invernizzi et al., 2007) and in vitro
(Rick et al., 1995; Stanford and Lacey, 1996;
Gongora-Alfaro et al., 1997) evidence, it is
possible to speculate that 5-HT released in vivo
elicits a direct excitatory response in a discrete
population of SNr neurons, probably resulting in
the expression of 5-HT2C, which in turn inhibits a
greater number of neighbouring SNr cells through
GABA release from their extensive axon collat-
erals (Mailly et al., 2003; Invernizzi et al., 2007).
Therefore, the source of GABA in the SNr might
have many different origins — i.e. it might derive
from a subpopulation of GABA-containing neu-
rons in the SNr that are excited by 5-HT2C
agonists, from release of GABA by the somato-
dendritic regions and their recurrent collaterals
and/or from the GPe neurons excited, in turn, by
the STN. We can exclude a striatal GABA source
since its neurons are principally inhibited by
5-HT2C receptor agonists.
The overall effect of activation of 5-HT2C
receptors, therefore, would be the overinhibition
of nigrothalamic GABAergic neurons and conse-
quent decrease of GABA levels in the motor
thalamus. According to the current model of basal
ganglia functional organization (DeLong, 1990),
reduction of the subthalamonigral GLUergic
excitatory drive and/or increase in the GABAergic
inhibitory inﬂuence on nigrothalamic GABAergic
neurons lead to disinhibition of thalamocortical
GLUergic projections and movement initiation
(Deniau and Chevalier, 1985). Thus, drugs acting
at 5-HT receptors might be useful in treating
akinesia and other parkinsonian symptoms chara-
cterized by an overactivity of the nigrothalamic
pathway (Deniau and Chevalier, 1985; DeLong,
1990).
Strikingly, under physiological conditions,
5-HT2C receptors do not exert any tonic control
on the basal ganglia activity, although blocking
these receptors in the striatum leads to an increase
of DA release. Indeed, there is evidence that a
number of selective 5-HT2C antagonists, such as
SB 200646A, SB 206553 and SB 242084, do not
elicit locomotory activity, when given alone
(Kennett et al., 1994, 1996, 1997). Moreover,
intranigral infusion of the antagonist SB 206553
into the SNr on the unlesioned side of a 6-OHDA-
lesioned rat did not elicit a signiﬁcant rotational
response (Fox et al., 1998).
On the other hand, it has been shown that
5-HT2C receptor transmission may be a key
determinant in the activity of SNr in parkinsonian
basal ganglia. Accordingly, infusion of SB 206553
into the SNr on the 6-OHDA-lesioned side elicited
a marked rotational response contraversive to
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the injection (Fox et al., 1998). Such behaviour
represents a reduction in the activity of basal
ganglia outputs and can be taken as representing
a potential anti-parkinsonian action. Moreover,
systemic administration of SB 206553 enhanced
the action of D2 agonist quinpirole and D1 agonist
SKF 82958 in eliciting a rotational response
contraversive to the lesioned side (Fox et al.,
1998; Fox and Brotchie, 2000a). The mechanism
whereby 5-HT2C receptor antagonists enhance the
anti-parkinsonian action of DA receptor agonists
may involve reducing the overactivity of the SNr.
When given alone, 5-HT2C receptor antagonists
may be capable of reducing the activity only to a
certain degree following systemic administration.
Therefore, there may not be a sufﬁcient reduction
in the activity of the SNr to restore the normal
thalamocortical output and have an overt anti-
parkinsonian effect.
From these ﬁndings, it is clear that in the
6-OHDA PD model, the antagonists at 5-HT2C
receptors show anti-parkinsonian effects and are
probably decreasing SNr activity, an effect
obtained in normal rats with the agonists instead.
We explained this paradox suggesting that under
pathological conditions, when the basal ganglia
circuitry is impaired by DA depletion, the 5-HT2C
receptor transmission is also altered. The over-
expression of 5-HT2C receptors in the SNr could
lead to a clear-cut excitatory effect on the
output structures since the indirect collateral
inhibition is totally overcome. Thus, the conse-
quence is a contribution to the SNr overactivity
that is known to be a hallmark of PD and related
disorders (Di Giovanni et al., 2006b). 5-HT2C
receptor transmission may be a key determinant in
the activity of the SNr in parkinsonian basal
ganglia and its selective activation in this condition
might have a surprising opposite effect compared
to that which it has on the ‘normal’ circuitry.
Studies are underway in our laboratories to verify
this supposition.
In addition, the blockade of 5-HT2A/2C recep-
tors is a determinant of the effect of clozapine
and risperidone in inhibiting the discharge of
SNr neurons (Bruggeman et al., 2000). Indeed,
Bruggeman et al. (2000) showed that concurrent
5-HT2A/2C and moderate DA D2 receptor anta-
gonism can mimic the in vivo effects of these
atypical antipsychotics on the ﬁring rate of SNr
neurons. Therefore, the inhibitory effect of the
atypical antipsychotics clozapine and risperidone
and of concurrent 5-HT2/D2 antagonism on the
SNr may reﬂect a mechanism to counteract motor
side effects [extrapyramidal symptoms (EPS)] by
disinhibiting thalamocortical circuits.
On the other hand, it could also be a mechanism
to alleviate negative symptoms. This is based on
the fact that the SNr, aside from prominent
innervations from the dorsolateral striatum, also
receives afferents from the nucleus accumbens,
innervating subﬁelds of the mediodorsal and
ventromedial thalamic nuclei mainly afﬁliated to
the prelimbic area and the prefrontal cortex.
Therefore, one must consider that changes in SNr
activity may reﬂect not only motor activity — and
in that sense EPS — but also emotional and
motivational processes, which may be involved in
negative symptoms.
5-HT modulation of STN activity
The STN is an important mediator of the output
circuits subserving basal ganglia motor function,
and a potent link between the serotonergic system,
the STN and motor behaviour has been high-
lighted. It is interposed in the direct pathway
between the external segment of the GP (GPe) and
the GP (GPi)/SNr. The STN also has projections
that interact with the other primary output path-
way from the striatum, the direct pathway, at the
level of the GPe (Kita and Kitai, 1987; Shink et al.,
1996). This connectivity provides the STN with a
unique ability to mediate basal ganglia motor
function, and accordingly, the STN has a strong
inﬂuence on motor behaviour related to basal
ganglia DAergic neurotransmission. For instance,
the STN has been implicated in the mediation of
parkinsonian movement disorders. An increase in
the basal activity of the excitatory GLUergic
afferent neurons of the STN, associated with the
loss of DA terminals in the striatum, may play a
role in the hypokinetic symptoms of this condition
(Smith and Grace, 1992). Indeed, STN lesion, as
well as its inactivation by deep brain stimulation
(DBS), has shown to have anti-parkinsonian
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effects in an experimental primate model of
PD and in PD patients (Krack et al., 1998;
Charles et al., 2004; Sturman et al., 2004).
Under normal DA function, in both humans and
primates, unilateral lesions of the STN result in
hemiballism and chorea, which are characterized
by involuntary, hyperkinetic movements of the
contralateral limbs (Mitchell et al., 1985; Bhidaya-
siri and Truong, 2004). During the past decade,
patients suffering from PD have undergone
modulation of this STN hyperactivity by high-
frequency stimulation (HFS) (Limousin et al.,
1995). HFS of the STN has dramatic therapeutic
effects on locomotor symptoms (Krack et al.,
2003). The mechanism by which STN HFS
improves locomotor symptoms is not well under-
stood, but some evidence suggests that HFS
modulates the pathological activity within the
STN (Garcia et al., 2005), lowering GABA release
in the motor thalamus (Stefani et al., 2006).
On the other hand, it is known that 5-HT
neurons, mainly from the DRN, innervate the
STN and clearly modulate its neuronal activity.
5-HT may have multiple actions in the STN.
Whole-cell patch-clamp and extracellular single-
unit recordings on rat brain slices with selective
5-HT agonists and antagonists indicated both
5-HT1A receptor-mediated inhibitory and 5-HT2C
and 5-HT4 receptor-mediated excitatory responses
of 5-HT in subthalamic neurons (Stanford et al.,
2005; Shen et al., 2007). In addition, 5-HT inhibits
synaptic transmission in the STN by activating
presynaptic 5-HT1B receptors. Indeed, in a recent
electrophysiological study in slices of rat brain,
5-HT reduced the amplitude of both GLUergic
excitatory postsynaptic currents (EPSCs) and
GABAergic inhibitory postsynaptic currents
(IPSCs) on the STN neuron membrane (Shen and
Johnson, 2008). The 5-HT-induced inhibition of
synaptic currents was associated with a signiﬁcant
increase in the paired-pulse ratios of evoked
EPSCs and IPSCs, suggesting that 5-HT acts
presynaptically to suppress both GLU and
GABA release. However, 5-HT was more potent
for reducing EPSCs compared to IPSCs (Shen and
Johnson, 2008). This inhibitory effect was
mediated via the activation of 5-HT1B receptors
because selective 5-HT1B antagonists blocked
5-HT-induced inhibition of EPSCs and IPSCs
(Shen and Johnson, 2008). Consistent with its
presynaptic location, 5-HT1B receptor activation
has been shown to cause presynaptic inhibition of
GABA-mediated transmission in the SN also
(Johnson et al., 1992; Stanford and Lacey, 1996).
According to a widely used model of basal ganglia
function, a reduction in excitatory glutamate input
to the STN would be expected to improve the
symptoms of PD (Bonsi et al., 2007b). Indeed,
injection of 5-HT1B agonists systemically
(Oberlander et al., 1987; Rempel et al., 1993) or
into the STN (Martinez-Price and Geyer, 2002)
has been reported to increase locomotion in rats.
However, 5-HT1B receptor stimulation has also
been reported to reduce L-DOPA-induced dyski-
nesia (LID) in a rat model of PD (Carta et al.,
2007), which is not what one would predict based
on inhibition of excitatory input to the STN.
Moreover, 5-HT1B agonists have also been
reported to interfere with the beneﬁt of L-DOPA
in a marmoset model of PD. Activation of 5-HT1B/1D
receptors induced motor deﬁcits and inhibited
motor responses to L-DOPA, whereas blockade of
5-HT1B receptors had no observable effects on
motor behaviours (Jackson et al., 2004). These
data suggest that neither stimulation nor blockade
of 5-HT1B receptors will be therapeutically bene-
ﬁcial to the treatment of PD or drug-induced
dyskinetic syndromes.
The 5-HT2C receptors are most likely to be
involved in 5-HT effects since they are present in a
relatively high concentration in this nucleus. The
most frequent response to 5-HT seems to be an
excitation of STN neurons (Flores et al., 1995;
Stanford et al., 2005; Xiang et al., 2005; Shen et al.,
2007). This effect is mediated by the activation of
the 5-HT2C and 5-HT4 receptors being reversed by
the combined use of selective antagonists for
5-HT4 and 5-HT2C receptors (Stanford et al.,
2005; Xiang et al., 2005). In addition, Shen et al.
(2007) found that STN neuron burst ﬁring was
facilitated by 5HT2C- and 5HT4-dependent cur-
rents, and since excessive burst ﬁring of STN
neurons has been implicated in the expression of
the symptoms of PD, it was suggested that
antagonists at 5HT2C or 5HT4 receptors might
be useful in the treatment of PD. Moreover, an
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inhibitory action of 5-HT over a small subpopula-
tion (about 20%) of STN neurons has been also
shown (Stanford et al., 2005, Shen et al., 2007),
and it seems to be mediated by 5-HT1A receptor
activation (Stanford et al., 2005). Thus, this
electrophysiological evidence indicates that
5-HT-induced excitation and inhibition in the
STN are separate entities and most likely to arise
as a consequence of independent, direct postsy-
naptic effects mediated by 5-HT2C, 5-HT4 and 5-
HT1A subtypes. The excitatory 5-HT effect
through the activation of 5-HT2C receptors is in
accordance with the results of a recent study that
investigated the effect of subthalamic DBS, using
clinically relevant stimulation parameters, on
DOI-induced hypomobility (Hameleers et al.,
2007). These authors found that administration
of DOI decreased the locomotor activity, as
evidenced by a net decrease in the distance moved,
the velocity and the time spent in moving. This
decrease in locomotion was reversed by DBS of the
STN. Varying results of DOI administration on
locomotion have been obtained in the past. Some
studies showed an increase in locomotor activity
after DOI administration (Darmani et al., 1996;
Granoff and Ashby, 1998); some authors found no
effects (Hawkins et al., 2002), and others demon-
strated hypomobility in rats treated with DOI
(Krebs-Thomson and Geyer, 1996). It is probably
the concentration of DOI that is contributing to
the difference in these studies. In their study,
Xiang et al. (2005) found a clear reduction of
locomotor activity, which was reversed by STN
HFS. It is known that injection of 5-HT2A and 5-
HT2C agonists can increase the ﬁring rate of STN
neurons (Xiang et al., 2005). Since DOI activates
these receptors, it is likely that DOI excites STN
neurons and induces increased STN activity.
Increased STN activity is thought to be responsible
for the hypokinesia in PD. In addition, these
ﬁndings support the hypothesis that 5-HT2 recep-
tors may mediate the therapeutic effects of STN
HFS on locomotor symptoms.
However, this evidence is not in accordance with
a large body of behavioural evidence that shows an
inhibitory action of 5-HT over the STN by acting
on 5-HT2C receptors. As a result, a decrease in the
excitatory input from the STN to GPe/SNr occurs,
which in turn enhances the activity of the
ipsilateral motor thalamus. Indeed, the unilateral
injection of 5-HT into the STN induces a
contralateral dose-dependent turning behaviour,
which is blocked by the unselective 5-HT2 antago-
nist mianserin. The contribution of the 5-HT2C
receptor in 5-HT-induced behaviour was revealed
by the intrasubthalamic injection of the 5-HT2C
receptor agonist MK 212 that, in concordance,
increased the net turns (Belforte and Pazo, 2004).
In addition, the blockade of subthalamic 5-HT2C
receptors suppressed the stereotypic behaviour
induced by apomorphine administration (Barwick
et al., 2000) while both systemic administration
and local unilateral infusion of mCPP into the
STN induced an increase in oral movements in rats
(Eberle-Wang et al., 1996; De Deurwaerdere and
Chesselet, 2000; Mehta et al., 2001) that resemble
the orofacial dyskinesias occurring as a severe side
effect of prolonged treatment with antipsychotic
drugs in humans (Waddington et al., 1986; Ellison,
1991). Oral dyskinesia observed after peripheral
injections of mCPP was enhanced by 5,7-DHT-
induced lesion of the serotonergic neurons, prob-
ably due to an altered sensitivity to 5-HT2C
receptor stimulation in the STN (Mehta et al.,
2001). Interestingly, these authors observed
mCPP-induced seizure-like behaviours in a subset
of lesioned rats that were never observed in sham-
lesioned animals, thus demonstrating a pivotal
role for the 5-HT2C receptor in the control of
the normal neuronal excitability, a phenomenon
already noted by others (Mehta et al., 2001).
Despite the fact that the mechanism by which
serotonergic inputs to the STN contribute to its
normal functioning remains controversial, the
behavioural data discussed above clearly suggest
that excess stimulation of 5-HT2C receptors in this
region may lead to hyperkinetic movement dis-
orders. Thus, 5-HT2C antagonists can be useful to
treat the side effects of long-term administration
of neuroleptics in schizophrenia (Tarsy and
Baldessarini, 1984; Reynolds, 2004). Serotonergic
projections from the DRN and the MRN inner-
vate all components of the basal ganglia circuitry;
thus, there is evidence that endogenous 5-HT
induces excitations of the STN neurons through
several types of 5-HT receptors (Belforte and
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Pazo, 2004; Stanford et al., 2005; Xiang et al.,
2005). Since this nucleus is considered to be a
major driving force in the basal ganglia circuit
(Albin et al., 1989; Utter and Basso, 2008), it is
important to understand the role of the various
5-HT receptor subtypes in the control of this area.
With regard to the other 5-HT receptors, besides
5-HT1A, 5-HT1B, 5-HT2A and 5-HT2C, there is
evidence that only the 5-HT3 and 5-HT4 receptors
are involved in the control of the subthalamic
neurons. Unilateral injection of 5-HT into the
STN induced a contralateral dose-dependent turn-
ing behaviour, attributed to a decreased excitatory
input from the STN to the SNr, which in turn
enhanced the activity of the ipsilateral motor
thalamus (Belforte and Pazo, 2004). Similar results
were also observed with microinjections of quipa-
zine, a mixed 5-HT2B/2C/3 agonist, MK 212, a
5-HT2B/2C agonist, and m-chlorophenylbiguani-
dine, a 5-HT3 agonist (Belforte and Pazo, 2004).
Furthermore, kainic acid lesion of the SNr
suppressed the contralateral rotations elicited by
the stimulation of 5-HT2B/2C and 5-HT3 subtha-
lamic receptors (Belforte and Pazo, 2004). Taken
together, these data suggest that 5-HT tonically
stimulates the subthalamonigral pathway, through
5-HT2C and 5-HT3 receptor subtypes, without
involving the DAergic innervation of the nucleus,
because stimulation of subthalamic 5-HT recep-
tors in animals bearing a lesion of the nigrostriatal
pathway did not modify this motor response
(Belforte and Pazo, 2004).
The stimulating action of 5-HT on the STN is
further conﬁrmed by electrophysiological investi-
gations. Endogenous application of 5-HT in
mouse and rat brain slices increased the ﬁring
frequency of subthalamic neurons (Flores et al.,
1995; Stanford et al., 2005; Xiang et al., 2005).
The increased ﬁring rate of these neurons was
attributed to the depolarization of membrane
potential caused by a reduction of potassium
conductance mediated by 5-HT2C and mainly by
5-HT4 receptor subtypes (Stanford et al., 2005;
Xiang et al., 2005). Using several serotonergic
agonists and antagonists, Xiang et al. (2005) found
that only a-methyl-5-HT, a 5-HT2 agonist with
good afﬁnity for 5-HT4 receptors, and cisapride,
a 5-HT4 agonist, mimicked the action of 5-HT.
Furthermore, the 5-HT action was partially
reversed by the 5-HT4 antagonist SB 23597-190,
the 5-HT2 antagonist ketanserin and the 5-HT2C
receptor antagonist RS 102221; in addition, the
effect of RS 102221 was comparable with that of
ketanserin. Therefore, it was concluded that 5-HT4
and 5-HT2C receptor subtypes are involved in the
excitatory action of 5-HT in STN neurons and
may be co-localized in a single neuron (Xiang
et al., 2005). These data were replicated by
Stanford et al. (2005), who showed that the pre-
infusion of RS 102221 and GR 113808, another
5-HT4 antagonist, reduced excitations of STN
neurons induced by local application of 5-HT. On
the basis of these results, it was concluded that
when there is the cortical activation for a speciﬁc
movement, a group of raphe serotonergic neurons
that project to the STN and STN neurons
themselves might be simultaneously activated,
then amplify subthalamic activity and conse-
quently facilitate the excitation of the output
structures in the basal ganglia, which in turn
inhibits the thalamic motor area (Xiang et al.,
2005). In the classical rate model of basal ganglia
function, the neural mechanisms underlying the
generation of parkinsonian symptoms are thought
to involve reduced activation of primary motor
and premotor cortex, and supplementary motor
areas secondary to an over-activation of the
output regions of the basal ganglia, i.e. SNr and
GPi (Albin et al., 1989), largely because of
excessive excitatory drive from the STN, conse-
quent to DA loss in the striatum (Nicholson and
Brotchie, 2002; Utter and Basso, 2008). Hence, it is
theoretically possible that antagonists at the
5-HT2C and 5-HT4 receptors, which act directly
to reduce STN neural activity, may have positive
therapeutic beneﬁts in PD.
5-HT modulation of GP activity
Anatomical and experimental evidence supports a
pivotal role for 5-HT in the control of neuronal
activity of both the GPe and the GPi, which
express several 5-HT receptors. Perkins and Stone
(1983) found that typical high-frequency ﬁring
GPe neurons in anaesthetized rats were not
responsive to iontophoretically applied 5-HT, and
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5-HT inhibited a small number of low-frequency
ﬁring GPe neurons. In contrast, Querejeta et al.
(2005) found that local application of a 5-HT
receptor agonist, or ﬂuoxetine, excites most of the
GPe neurons in anaesthetized rats, showing the
presence of a serotonergic excitatory tone on GP
neurons. This evidence was further conﬁrmed by a
recent patch-clamp recording study (Chen et al.,
2008). In reality, the effect of 5-HT is more
complex because of the existence of various
receptor subtypes on presynaptic and postsynaptic
membranes in the pallidum. In fact, recent
electrophysiological evidence has shown that
5-HT exerts strong modulation on inhibitory and
excitatory responses to cortical stimulation in the
GPe and the GPi (Kita et al., 2007; Hashimoto
and Kita, 2008). 5-HT suppressed GABAergic
inhibitory responses to cortical stimulation in
monkeys, through presynaptic 5-HT1B receptors,
densely expressed on axons and axon terminals in
the pallidum (Kita et al., 2007). On the other hand,
5-HT1A receptors are involved in the suppression
of GLUergic excitations of the GP because local
application of WAY 100635, a 5-HT1A selective
antagonist, blocked the effect of subsequent
applications of 5-carboxamindotryptamine (5-CT)
in suppressing cortical stimulation-induced excita-
tions (Kita et al., 2007). Hence, 5-HT may reduce
ionotropic GLUergic excitation, probably through
5-HT1A receptors located at presynaptic and/or
postsynaptic sites. On pallidal neuron slices, 5-HT
and 5-CT presynaptically reduce glutamate release
in the GPe, and the antagonistic effect of GR 55562
suggested an involvement of 5-HT1B/1D receptors in
this effect (Hashimoto and Kita, 2008).
In accordance with these ﬁndings, an in vivo
electrophysiological study reported that local
application of the 5-HT1B receptor agonist
L-694247 excited most GPe neurons, which can
be due to presynaptic suppression of GABAergic
inhibitions, in anaesthetized rats (Querejeta et al.,
2005). In addition, the effect of 5-HT in the
electrical activity of GP neurons of rats with
unilateral quinolinic acid striatal lesions was
severely attenuated, indicating that presynaptic
5-HT1B receptors modulate GABA release from
striatopallidal terminals (Querejeta et al., 2005).
Taken together, these data indicate that the tonic
activation of 5-HT1B receptors signiﬁcantly con-
tributes to the decrease of GABA release from
striatopallidal GABAergic terminals facilitating
GP neurons’ spiking; on the other hand, the
blockade of these receptors causes a signiﬁcant
decrease on the spiking frequency of GP neurons
due to the augmented GABA release from
striatopallidal terminals (Querejeta et al., 2005).
In line with these studies, 5HT1B receptor activa-
tion with CP-93129 inhibited the release of
[3H]-GABA from pallidal slices, and intrapallidal
injection of CP-93129 alleviated akinesia in the
reserpine-treated rat model of PD, indicating that
some 5HT1B receptors can function as heterore-
ceptors in the GP, reducing the release of GABA
from striatopallidal neurons. This cellular mechan-
ism underlies the anti-akinetic activity of CP-93129
seen in the reserpine-treated rat model of PD
(Chadha et al., 2000).
The application of 5-HT into the superfusion
medium of brain slices containing GP neurons
directly stimulated the receptors of the recorded
neurons and produced a reversible depolarization
of their membrane that consequently increased
the ﬁring rate of these neurons (Chen et al., 2008).
5-HT postsynaptic excitation of pallidal neurons
occurs through activation of 5-HT4 or 5-HT7
receptors but not via 5-HT2C and 5-HT3 receptors
(Bengtson et al., 2004; Kita et al., 2007; Chen
et al., 2008; Hashimoto and Kita, 2008).
These ﬁndings support the hypothesis that the
increase of 5-HT tone, which mainly excites
pallidal neurons directly and counteracts the
inhibition from the striatum selectively, will exert
an anti-parkinsonian effect.
5-HT in PD and other motor disorders
Parkinson’s disease
PD is the second most common neurodegenerative
disease in the elderly population with an inevitable
exitus. The idiopathic form is a progressive
disorder, the impact of which reaches far beyond
the clinical signs and symptoms exhibited by those
afﬂicted. Clinical features at presentation include
the asymmetric onset of cardinal motor symptoms
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such as tremor at rest, bradykinesia, muscular
rigidity, stooped posture and instability (Sian
et al., 1999).
Since Hornykiewicz’s pioneering work in identi-
fying the SNc as the site of major pathological
change in PD, reduced DAergic innervation of the
striatum has been thought to be central to its
pathogenesis (Hornykiewicz, 1973). Hitherto, the
underlying mechanisms of neuronal loss in
patients are not known. Therefore, current thera-
pies work mainly to alleviate symptoms rather
than to halt the progression of the disease (Di
Giovanni, 2008). There have been major advances
in understanding the aetiopathogenesis of PD and
the modalities whereby the neurodegenerative
process begins and progresses; therefore, the
development of drugs to slow and halt DAergic
neuronal degeneration or even to prevent the
disease now seems realistic (Esposito et al.,
2007a, b, c; Di Giovanni, 2008).
The modulation of 5-HT of the basal ganglia
nuclei has obvious implications for the treatment
of a range of motor diseases, most notably
including PD, LID and antipsychotic-induced
extrapyramidal effects. It has become axiomatic
that manipulation of 5-HT transmission may be
pivotal in treating the symptoms and of key
importance in improving symptomatologies in
this patient set (Nicholson and Brotchie, 2002;
Di Giovanni et al., 2006a, b; Scholtissen, et al.,
2006).
Although 5-HT involvement in PD has long
since been known (Scatton et al., 1983; Miyawaki
et al., 1997), the neuropathological literature on
the status of the DRN in PD is not entirely clear.
In fact, both loss of 5-HT cells bodies and no
modiﬁcation in their number in PD have been
reported (Sawada et al., 1985; Jellinger, 1987;
Halliday et al., 1990; Paulus and Jellinger, 1991;
Kim et al., 2003). Notwithstanding, in primates,
surgical lesion of upper brain stem producing
contralateral resting tremor and bradykinesia were
associated with reduced homolateral striatal 5-HT
(Goldstein et al., 1969). Compelling evidence
instead exists about damage of the ascending
pathways limited to the nerve terminal of 5-HT
neurons in different brain regions of PD patients
(Chase and Ng, 1972; Chase, 1974; Chinaglia
et al., 1993). Indeed, postmortem examinations
have shown a reduction of up to 50% of 5-HT in
some areas of the cortex and the basal ganglia
(Scatton et al., 1983; Birkmayer and Riederer
1986; Birkmayer and Birkmayer, 1987). Unlike
the preferential loss of DA in the putamen, the
caudate is affected more than the putamen by loss
of all 5-HT markers: 5-HT (66%), 5-hydroxy-
indolacetic acid (5-HIAA; the major 5-HT meta-
bolite) (42%), 5-HT transporter (5-HTT)
(56%) and tryptophan hydroxylase (TPH; the
marker synthetic enzyme) (59%) (Kish et al.,
2008). Reduced brain levels of all of the key
markers for the 5-HT neurotransmitter system
provide compelling evidence for a striatal seroto-
nergic abnormality in PD. This evidence has been
conﬁrmed by antemortem studies and imaging
investigations that showed reduced cerebrospinal
ﬂuid levels of 5-HIAA and decreased activity of
5-HTT not only in the caudate nucleus and the
putamen but also in the thalamus and medial
frontal areas, indicating a pathophysiological
involvement of 5-HT in PD (Haapaniemi et al.,
2001; Kerenyi et al., 2003; Kim et al., 2003). It
is, however, very likely that the degree of
serotonergic degeneration depends on the stage
of the disease (Scholtissen et al., 2006). Never-
theless, Bjorklund’s group recently showed that
serotonergic innervation of the striatal complex
remains relatively intact in most PD patients
(Carta et al., 2007).
5-HT receptors’ expression in PD animal models
and in patients
Animal models are important tools in experimen-
tal medical science to better understand the
pathogenesis of human diseases such as PD.
However, preclinical research on these animal
models has provided inconsistent results, high-
lighting that these experimental models represent
only an imperfect replica of human disorders
(Scholtissen et al., 2006).
The ﬁrst PD animal model developed is the
6-OHDA; this agent selectively disrupts catecho-
laminergic systems and reproduces speciﬁc features
of PD in rodents, apparently via oxidative damage
(Simola et al., 2007 and references therein).
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6-OHDA-lesioned animals have been exploited to
test therapeutic approaches for treating functional
disturbances observed in this disease and will aid
the future development of rational therapeutic
strategies. The 6-OHDA lesion can be performed
in adult or neonatal rats, producing different
changes in behaviour and the neurochemistry of
these animals, according to the age of the lesion
(Breese et al., 2005).
Although independently of the age in which
the SNc is injured, 6-OHDA leads to permanent
DA ablation while the serotonergic projection to
the striatum remains intact. Contrasting results
of the activity of DRN serotonergic neurons in
6-OHDA-lesioned rats exist; an increase in fre-
quency and burst ﬁring activity (Chu et al., 2004;
Zhang et al., 2007) or a decrease (60%) of
discharge rate (Guiard et al., 2008) has actually
been reported.
Both neonatal and adult lesions actually lead to
a 5-HT axonal hyperinnervation within the dorsal
striatum (Stachowiak et al., 1984; Breese et al.,
1985; Zhou et al., 1991; Molina-Holgado et al.,
1994; Mrini et al., 1995; Balcioglu et al., 2003;
Maeda et al., 2003). Consistently, striatal 5-HT
levels and 5-HTT binding have been reported to be
increased in this animal model of PD (Commins
et al., 1989; Zhou et al., 1991; Guerra et al., 1997;
Mendlin et al., 1999; Balcioglu et al., 2003).
Interestingly, it has been proposed that striatal
‘reactive’ serotonergic hyperinnervation in
lesioned animals occurs to compensate for the lost
function of DAergic terminals and this might
‘mask’ the true extent of the 5-HT loss in PD.
This suggests that 5-HT neurotransmission is
impaired and the clariﬁcation of the pathophysio-
logical mechanism can provide unique information
regarding the treatment of parkinsonism from a
point of view that differs from conventional therapy.
In addition to DA depletion, a discrete modi-
ﬁcation in the regulation of postsynaptic 5-HT
receptors in different areas of the basal ganglia
circuitry and in other brain areas has been
observed in animals and humans (Kienzl et al.,
1981; Radja et al., 1993). Therefore, alterations of
5-HT binding constants in PD might reﬂect an
imbalance in serotonergic activity.
5-HT1A binding is not altered in the basal
ganglia nuclei of neonatally 6-OHDA-lesioned
rats. In contrast, there is a considerable increase
in binding for 5-HT1B receptors. The highest
increase of 5-HT1B binding sites is observed in the
SN (54%), the GP (33%) and the two portions of
neostriatum. The most likely explanation for the
present increases in the neostriatal, nigral and
pallidal regions is therefore an augmented produc-
tion (up-regulation) of these receptors by the
neostriatal projection neurons and concomitant
increase of their axonal transport to both terri-
tories of projection. In view of its widespread
distribution in the neostriatum, it also seemed
likely that the neostriatal increase in 5-HT1B
binding was somehow related to the DA denerva-
tion of this brain region rather than to its
subsequent 5-HT hyperinnervation, suggesting a
possible role for DA in the regulation of 5-HT
receptor expression during ontogenesis. A signiﬁ-
cant increase in the density of 5-HT2C was also
revealed throughout the neostriatum (40%) and in
the SN (50%), but unchanged in the GP, as if this
up-regulation preferentially involved striatonigral
as opposed to striatopallidal neurons (Radja et al.,
1993).
Consistently, enhanced responses of sponta-
neously ﬁring units to iontophoresed 5-HT and
both 5-HT2C and 5-HT2A agonists have been
demonstrated in the 5-HT-hyperinnervated neo-
striatum after neonatal 6-OHDA lesion (el Mansari
et al., 1994). 5-HT2A binding showed an even
greater increase (60%), which was restricted to the
rostral half of the neostriatum and also seemed
imputable to an up-regulation as heteroreceptors.
5-HT2A receptor expression increases signiﬁcantly
on direct pathway neurons (Laprade et al., 1996;
Basura and Walker, 1999), even though 5-HT2A
receptors are expressed on both direct and indirect
striatal projecting neurons (Ward and Dorsa,
1996).
The intracellular mechanisms that mediate the
effects of 5-HT within the neonatal lesioned
striatum are poorly understood. Neonatal lesions
result in altered expression of preprotachykinin
(decrease) and preproenkephalin (increase) in
direct and indirect striatal pathway neurons,
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respectively (Sivam et al., 1987). It has been shown
that 5-HT acting via 5-HT2 receptors could
regulate preprotachykinin expression selectively
in direct pathway neurons and ultimately motor
function, after neonatal DA depletion (Basura
and Walker, 2001). Recently, it has been shown
that neonatal but not adult 6-OHDA lesions
result in a novel coupling of 5-HT2A receptors to
the ERK1/2/MAP kinase pathway, a signalling
cascade known to regulate neuronal plasticity
that is not typically active in these neurons.
Because DA-mediated signalling is redundant
after 6-OHDA lesions, 5-HT-mediated stimulation
of the ERK1/2/MAP kinase pathway may provide
an alternative signalling route allowing the regula-
tion of neuronal gene expression and neuronal
plasticity in the absence of DA (Brown and
Gerfen, 2006).
In adult rats, destruction of the nigrostriatal DA
projection by 6-OHDA has not been found to
modify [3H]5-HT binding in the neostriatum
(Quirion and Richard, 1987).
Consistently, in situ hybridization and autora-
diographic radioligand studies from lesioned rats
and human postmortem tissue from patients with
PD have revealed that striatal 5-HT1A (Numan
et al., 1995) and 5-HT1B (Zhang et al., 2008) are
not inﬂuenced by DA depletion. In the striatum,
5-HT2A receptors appear to be up-regulated
(Numan et al., 1995) and 5-HT2C receptors
down-regulated (Numan et al., 1995; Zhang et al.,
2007) or not affected (Basura and Walker, 1999;
Fox and Brotchie, 2000b). Striatal 5-HT2A and
5-HT2C are therefore differently regulated in
6-OHDA-lesioned animals. There is no signiﬁcant
difference in 5-HT2C binding level for control vs.
PD tissue in the GPi and the GPe (Fox and
Brotchie, 2000b), and in the levels of 5-HT2C
mRNA between the intact and 6-OHDA-lesioned
hemispheres in the nucleus subthalamicus in
rats (Zhang et al., 2007). Conversely, 50% increase
in 5-HT2C receptor binding was observed in
6-OHDA-lesioned rats, strictly in accordance with
the evidence that 5-HT2C receptor binding in the
SNr of age-matched control tissue was less than
half that in the SNr of patients with PD (Radja
et al., 1993; Fox and Brotchie, 2000b).
This evidence highlights a selective change in
the 5-HT2C receptor activity only in the output
regions of the basal ganglia. 5-HT2C receptors’
up-regulation might be compensatory, being a
consequence of a decreased level of 5-HT in these
nuclei, thus indicating a role for them in the
neuronal mechanisms involved in PD (Fox and
Brotchie, 2000b).
It is noteworthy that L-DOPA/benserazide
treatment not only reversed the 6-OHDA-induced
levels of 5-HT2A mRNA in the striatum but also
caused a highly signiﬁcant reduction in the levels
of this receptor. In contrast, 5-HT2C mRNA was
not affected by L-DOPA/benserazide treatment
(Zhang et al., 2007). It can be concluded from
these ﬁndings that the regulation of 5-HT2A is
highly dependent on alterations in DA levels. In
contrast, striatal 5-HT2C appears to be regulated
by nigrostriatal cell loss and the reduced level(s) of
factor(s), other than DA, such as brain-derived
neurotrophic factor (BDNF) and cholecystokinin,
which are normally expressed in nigrostriatal
neurons. Similarly, numerous studies conducted
in patients with PD and in animal models of
this disease, such as 6-OHDA-lesioned rats
and MPTP-treated primates, have shown that
L-DOPA-treatment does not adequately reverse
the effects of DA cell loss but rather creates a
new functional and neurochemical state, which
differs both from the normal and lesioned states
(Bezard et al., 2003). The fact that 5-HT2A, but not
5-HT2C, receptors are responsive to L-DOPA
treatment predicts that pharmacological manipu-
lations at 5-HT2C, but not at 5-HT2A, will result in
similar effects in PD patients whether they are
treated or not with DA replacement. These data
therefore support the notion that 5-HT2C receptor
antagonists may be useful as an adjuvant treat-
ment to DA agonists to treat motor complications
of PD (Fox et al., 1998; Di Giovanni et al., 2006a;
Zhang et al., 2007).
Consistent with these ﬁndings, systemic admini-
stration of the selective 5-HT2C antagonist SB
206553 was shown to enhance the action of the
anti-parkinsonian action of the DA D1 and D2
agonists in 6-OHDA-lesioned rats (Fox et al., 1998;
Fox and Brotchie, 2000a), suggesting that the use of
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a 5-HT2C receptor antagonist in combination with a
DA receptor agonist may reduce the reliance upon
DA replacement therapies. Hitherto, no studies
have been conducted in either non-human primates
or humans to address this issue.
5-HT3 binding is reduced in the entorhinal and
prefrontal cortices on the 6-OHDA-lesioned side
of the rat brain while no changes in the amygdala
and the hippocampus were observed (Cicin-Sain
and Jenner, 1993). Unfortunately, these authors
did not measure the 5-HT3 binding in the basal
ganglia. Nevertheless, it has been suggested that
the 5-HT3 blockade might be important in the
effect of the anti-parkinsonian agent talipexole
(Nishio et al., 1996).
No modiﬁcation of the distribution and density
of 5-HT4 receptor binding sites was observed in
6-OHDA-lesioned guinea pig basal ganglia —
neither in the caudate-putamen nor in the SN
itself (Vilaro et al., 2005). On the other hand,
following lesion of DA neurons by intranigral
injection of 6-OHDA, an increased 5-HT4 receptor
binding was instead observed in the caudal (59%),
but not the rostral, part of the caudate-putamen as
well as in the GP (93%) (Compan et al., 1996).
Since no decreases in 5-HT4 receptor density have
been detected in both studies (Compan et al., 1996;
Vilaro et al., 2005) after the DA lesion, it is likely
that these receptors are not expressed in DA
neurons but are located on terminals of striatal
projection neurons. Kainic acid lesions of the
caudate-putamen were associated with dramatic
local decreases in 5-HT4 receptor binding on the
injected side (89%), which suggested that striatal
neurons expressed 5-HT4 receptors. Correspond-
ing decreases of 72 and 20% in receptor density
were detected in the GP and the SN, consistent
with a presumed localization of 5-HT4 receptors
on striatal GABA neurons projecting to these
regions. In the SN, the decrease in [3H]GR 113808
binding was localized to the pars lateralis, indicat-
ing that striatal neurons belonging to the cortico-
striato-nigro-tectal pathway and containing
GABA and dynorphin express 5-HT4 receptors.
As yet, no experimental evidence has been found
about the modiﬁcation in expression of 5-HT5,
5-HT6 and 5-HT7 receptors in the basal ganglia of
an animal model of PD.
Role of 5-HT in LID
The abnormal involuntary movements, or dyski-
nesia, generated by prolonged administration of
L-DOPA represent one of the major challenges
facing current therapy for PD. These debilitating
motor disturbances are all the more problematic
because L-DOPA, in spite of its introduction
several decades ago, still represents the therapy
of choice for the treatment of PD. The discovery of
pharmacological interventions able to counteract
LID would therefore represent an important
breakthrough in the therapy for PD. The design
of novel agents for the prevention and treatment of
LID requires the elucidation of the adaptive
changes produced in the parkinsonian brain by
repeated administration of L-DOPA and the
assessment of their role in the development and
expression of this condition. Recently, compelling
evidence has been produced about the causative
role of 5-HT in LID developing in both animal
models and PD patients, suggesting a use of
serotonergic agents in reducing LID in PD patients
(Jackson et al., 2004; Johnston and Brotchie, 2006;
Carlsson et al., 2007; Carta et al., 2007). In fact,
5-HT neurons have been shown to be able to
convert exogenous L-DOPA to DA, and store and
release DA in an activity-dependent manner but
without the ﬁne control that occurs in DA release
by DA neurons (see Chapter 22). Therefore,
activation of the autoreceptors 5-HT1A and
5-HT1B, localized on the soma and terminals of
5-HT neurons, respectively, has been shown to be
highly effective in counteracting LIDs in the
6-OHDA rat model (Carta et al., 2007). The
rationale for the use of these agonists consists in a
possible modulation of DA release from 5-HT
neurons in a way that resembles the physiological
DA release from DA neurons. Hitherto, this
attractive hypothesis has not been validated by a
human study.
In addition, 5-HT2C receptors might be involved
in LID. The changes in 5-HT2C receptor binding
reported by Fox et al. (1998) were seen in PD
patients with LID. It is thus possible that they
could be ascribed to the process underlying
dyskinesia rather than parkinsonism (Fox et al.,
1998). Thus, reduced stimulation of 5-HT2C
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receptors would lead to decreased activity of the
basal ganglia output nuclei and increased levels of
abnormal movements. This hypothesis may pre-
dict an efﬁcacious use of 5-HT2C agonists for
alleviating the side effects of long-term treatment
with L-DOPA. This seems unlikely since clozapine
and quetiapine, antagonists for this receptor
subtype, have been used successfully for this
purpose (Durif et al., 2004). On the other hand,
systemic administration of the selective 5-HT2C
antagonist SB 206553 was shown to enhance the
anti-parkinsonian action of the DA D1 and D2
agonists in 6-OHDA-lesioned rats (Fox et al.,
1998; Fox and Brotchie, 2000a), suggesting that
the use of a 5-HT2C receptor antagonist in
combination with a DA receptor agonist may
reduce the reliance upon DA replacement thera-
pies. Hitherto, no studies have been conducted in
either non-human primates or humans to address
this issue. For a more extended treatment of this
subject, see Chapters 22 and 23.
Role of 5-HT in parkinsonian resting tremor
Furthermore, convincing evidence has indicated a
pivotal role of 5-HT in parkinsonian resting
tremor. The most common tremor seen in patients
with PD is a ‘pill-rolling’ movement of the hands
(Sethi, 2003). Despite a number of clinical and
basic studies, the neural substrate for this motor
complication remains unclear. The causative role
of 5-HT in tremorgenesis has been strengthened by
a recent PET study in PD patients (Doder et al.,
2003). Interestingly, these authors showed that
severity of parkinsonian tremor, but not rigidity or
bradykinesia, was correlated signiﬁcantly with this
decrease in midbrain raphe 5-HT1A binding, likely
reﬂecting a dysfunction and loss of serotonergic
cell bodies early in the disease process (Doder
et al., 2003). This evidence is in agreement with
the suggested hypothesis of ‘disequilibria’ in the
5-HT–histamine system responsible for tremor
(akathisia), whereas ‘disequilibria’ in the DA–ACh
system might lead to rigidity (akinesia) (Barbeau,
1962). A glimmer of light on the potential of
subtype-selective serotonergic agents for the relief
of parkinsonian tremor was recently thrown by
Carlson and colleagues (Carlson et al., 2003).
Local injections of a mixed 5-HT2A/2C receptor
antagonist into the SNr block tremulous jaw
movements in a cholinomimetic model of parkin-
sonian tremor in rats (Carlson et al., 2003). This
result is consistent with previous studies showing
that the jaw movement activity was suppressed
potently by clozapine, olanzapine and risperidone
(Ikeguchi and Kuroda, 1995; Trevitt et al., 1997,
1998) and clinical reports demonstrating seroto-
nergic involvement in the generation and treat-
ment of parkinsonian symptoms and other motor
disorders (Ikeguchi and Kuroda, 1995).
Role of 5-HT in psychiatric complications in PD
Besides being a movement disorder, PD is also
associated with numerous non-motor symptoms.
Mood disturbance, and especially major depressive
disorder, has an average prevalence of 25–40% in
outpatient settings (Leentjens, 2004; Veazey et al.,
2005; Miller et al., 2007). According to the
serotonergic hypothesis of depression in PD
(Mayeux, 1990), 5-HT seems to play a central
role. Indeed, it has been suggested that the reduced
DA activity in PD can lead, as physiological
adaptation, to a reduction of serotonergic tone
and, at the same time, constitute a risk factor for
depression (Mayeux, 1990). The presence of this
biological risk factor for depression may explain
the high prevalence of this condition in patients
with PD (Leentjens, 2004). Nevertheless, a recent
double-blind, randomized study provided no sup-
port for the serotonergic hypothesis of depression
in PD, using the acute tryptophan depletion
(ATD) paradigm (Leentjens et al., 2006). Co-
morbid depression in PD is usually treated with
SSRIs or tricyclic antidepressants (TCAs),
although these drugs should be used with caution
in patients with PD because they can exacerbate
orthostatic hypotension and anticholinergic
adverse effects (Veazey et al., 2005).
We have recently suggested that 5-HT2C recep-
tor antagonists prove useful in addressing depres-
sion and also, in PD patients, increasing the
activity of ventral tegmental area (VTA) DA
neurons and accumbal DA release (Di Giovanni
et al., 2006a, b). In accord with this, nefazodone, a
5-HT2 antagonist/reuptake inhibitor, has shown a
445
Author's personal copy
dual activity: as an antidepressant and as an agent
capable of reducing the EPS in depressed PD
patients (Avila et al., 2003). Given these desirable
motor side effects, nefazodone should be chosen
over SSRIs for the treatment of depression in
PD patients if they tolerate its use (Avila et al.,
2003).
Apart from depression, dementia and psychosis
are also common psychiatric problems associated
with PD. Psychotic complications are associated
with the use of anti-parkinsonian drugs and make
PD management more difﬁcult, given the need for
anti-DAergic therapy, which worsens motor func-
tioning in patients with PD. For psychosis,
clozapine is the only atypical antipsychotic that
has proven effective without worsening motor
function in PD patients. However, its use requires
the monitoring of agranulocytosis. Newer atypical
APDs, such as quetiapine, have been claimed to be
safe in terms of motor functioning, but evidence
about their effectiveness is not compelling. The
efﬁcacy of the atypical APDs in treating psychosis
in PD patients is likely to be due to their ability in
blocking 5-HT receptors. In fact, antagonists or
inverse agonists of the 5-HT2A and 5-HT2C
receptor are potential therapeutic agents for
treatment-induced psychosis of PD (Weiner
et al., 2003; Di Giovanni et al., 2006a).
Role of 5-HT in APD-induced extrapyramidal
side effects
In addition to the neurodegenarative, idiopathic
form, parkinsonian symptoms are also produced
by therapies using typical APDs such as halope-
ridol, a mixed DA antagonist. In fact, EPS are
common neurological side effects of APD medica-
tion. More than 60% of the people who take
conventional antipsychotic medications experience
some form of EPS. These side effects can occur
within the ﬁrst few days or weeks of treatment or
appear after months and years of antipsychotic
medication use. EPS are more common among
patients taking conventional antipsychotic medi-
cations, compared to the newer atypical drugs.
EPS can cause a variety of symptoms, e.g.
involuntary movements, tremors and rigidity,
body restlessness, muscle contractions and changes
in breathing and heart rate. Drug-induced EPS are
categorized into acute (acute dystonia, parkinson-
ism and akathisia) and delayed [tardive dyskinesia
(TD)] syndromes, based on the time of occurrence
during antipsychotic treatment. Neuroleptic-
induced parkinsonism is characterized by the triad
of tremor, rigidity and bradykinesia; it can closely
resemble idiopathic PD caused by nigrostriatal
degeneration. TD is the major limitation of long-
term APD therapy, being potentially irreversible.
This condition occurs in 15–30% of patients and
results in abnormal, unintentional choreoathetoid
movements of the head, limbs and trunk. The
incidence of akathisia, parkinsonian syndromes
and TD, which are relatively frequent in patients
treated with classical antipsychotic agents, is also
similar to that in patients treated with TCAs and
SSRIs. Amitriptiline, clomipramine, doxepine,
trazodone and ﬂuoxetine induce TD in patients
not previously treated with neuroleptics (Mander
et al., 1994; Clayton, 1995; Bharucha and Sethi,
1996), and akathisia, acute dystonia and pseudo-
parkinsonism have been induced by some of these
drugs, although not all share the same risk for the
development of movement disturbances.
It has been proposed that DA receptors’ super-
sensitivity, arising from up-regulation of DA2
receptors following APDs, is the base for the
development of TD. In addition to DA, 5-HT
receptors are also important in the aetiology of
schizophrenia and the elicitation of EPS. Particu-
larly 5-HT1A, 5-HT2A/2C and 5-HT3 receptor
signalling seems to be altered in TD. Recently,
a possible genetic predisposition to develop TD
exists, and association between TD and receptor
gene polymorphisms of 5-HT2A and 5-HT2C genes
has actually been shown (Gunes et al., 2007, 2008).
5-HT1A receptors may be important since the
postsynaptic 5-HT1A receptor density in the
prefrontal and temporal cortices of patients with
schizophrenia is elevated (Tauscher et al., 2002).
Probably, a resultant decrease in the normal
inhibitory serotonergic inﬂuence on motor activity
may be involved in the precipitation of TD in
patients on haloperidol therapy, since chronic
administration of haloperidol increased the
responsiveness of presynaptic and postsynaptic
5-HT1A receptors and reduced 5-HT turnover
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(Haleem and Khan, 2003). Consistently, repeated
administration of low doses of buspirone, a partial
agonist at 5-HT1A receptors, decreased the respon-
siveness of 5-HT1A receptors (Okazawa et al.,
1999) and reversed haloperidol-induced deﬁcits of
exploratory activity (Haleem et al., 2007a, b). In a
widely accepted rat model of TD obtained with
chronic treatment by neuroleptics (Ellison and See,
1989) 8-OHDPAT (Naidu and Kulkarni, 2001a)
and sarizotan, a 5-HT1A agonist/D3/D4 ligand
(Rosengarten et al., 2006) treatment inhibited
haloperidol-induced vacuous chewing movements
(VCMs). Consistently, buspirone reversed reser-
pine-induced dyskinetic movements in rats
(Queiroz and Frussa-Filho, 1999) and completely
reversed the induction of tardive VCMs (Haleem
et al., 2007a, b).
The evidence that buspirone, at low doses,
preferentially acts at the somatodendritic 5-HT1A
receptors further supports the hypothesis of
impaired somatodendritic 5-HT function (Haleem
and Khan, 2003; Haleem et al., 2007a, b). These
compelling experimental data support an impair-
ment of 5-HT transmission as a possible important
contributing factor in the onset of TD and other
parkinsonian-like effects of neuroleptics. Repeated
administration of haloperidol elicits an increase in
the responsiveness of somatodendritic and post-
synaptic 5-HT1A receptors. An increase in the
effectiveness of somatodendritic 5-HT1A receptors
in rats treated with haloperidol would be expected
to decrease the 5-HT input to DA nuclei.
Buspirone and 8-OHDPAT might act in reversal
of haloperidol-induced dyskinesia by desensitiza-
tion of 5-HT1A receptors, suggesting that prior
administration of buspirone may be of help in the
improvement of EPS induced by haloperidol and
other antipsychotic drugs (Haleem et al., 2004;
Samad et al., 2007).
5-HT2C receptor signalling is also deeply impli-
cated in the development of VCMs and 5-HT2C
receptors, which become supersensitized during
long-term haloperidol treatment and remain super-
sensitized even after withdrawal of haloperidol as
a treatment (Wolf et al., 2005; Ikram et al., 2007).
In fact, mCPP enhances the oral activity response
to a greater extent than the DA D1 receptor
agonist SKF 38393 in neonatal 6-OHDA-treated
rats (Gong and Kostrzewa, 1992). It is likely
that mCPP produces its effect at 5-HT2 (probably
5-HT2C) receptors being blocked by the largely
5-HT2 receptor antagonist mianserin (Gong and
Kostrzewa, 1992). Moreover, DA D1-induced
VCMs also appear to be mediated ultimately by
5-HT2C receptors and, as a result, are attenuated
by mianserin (Gong and Kostrzewa, 1992). It is
signiﬁcant that various 5-HT2 receptor antago-
nists, such as seganserin, ketanserin and ritanserin,
are able to effectively reduce the number of
spontaneous VCMs in a rat model of TD (Naidu
and Kulkarni, 2001a).
Concordantly, clozapine and other atypical
APDs that also have a high afﬁnity for 5-HT2C
receptors (Altar et al., 1986) reduced motor side
effect liability because of the same degree of
intrinsic anti-parkinsonian characteristics, which
act to counteract the pro-parkinsonian effects of
DA blockade. This was suggested by early clinical
studies indicating that the 5-HT2A/2C receptor
antagonist ritanserin (Leysen et al., 1985; Bersani
et al., 1990) can ameliorate negative symptoms as
well as attenuate exciting EPS in schizophrenics
treated with classical APDs (Bersani et al., 1990;
Miller et al., 1990). The relevance of 5-HT2C
receptor blocking in the effect of atypical APDs
was shown by Canton et al. (1990), who revealed
the high afﬁnity of clozapine and risperidone for
5-HT2C sites in the rat choroid plexus. These ﬁnd-
ings were subsequently conﬁrmed (Kuoppamaki
et al., 1993, 1995; Schotte et al., 1993; Canton
et al., 1994) and extended to brain sections
(Roth et al., 1992, 1998). Antagonism at 5-HT2C
receptors by several atypical antipsychotics was
also observed in vivo. Indeed, clozapine produces
an increase in extracellular levels of DA in the
nucleus accumbens (Di Matteo et al., 2002;
Shilliam and Dawson, 2005), reverses the inhibi-
tion of accumbal DA release induced by the
5-HT2C agonist Ro 60-175 (Di Matteo et al.,
2002) and blocks the hypolocomotion induced
by the 5-HT2C agonist mCPP (Prinssen et al.,
2000).
It is noteworthy that clozapine, like several
atypical APDs, behaves as a 5HT2C inverse agonist
in heterologous expression systems in vitro
(Herrick-Davis et al., 2000; Rauser et al., 2001;
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Navailles et al., 2006) and in vivo (Navailles et al.,
2006). Thus, the 5-HT2C receptor inverse agonist
might underlie the unique clinical properties of
atypical APDs, such as low EPS proﬁle and good
anti-dyskinetic efﬁcacy (Herrick-Davis et al., 2000;
Durif et al., 2004; Navailles et al., 2006).
Despite different chemical structures and phar-
macodynamic signalling pathways, a number of
antipsychotics inhibit ion ﬂuxes through 5-HT3
receptors in a noncompetitive manner, with the
exception of the known competitive antagonists
mirtazapine, olanzapine and clozapine (Bymaster
et al., 2001; Rammes et al., 2004; Eisensamer et al.,
2005). In accord with these ﬁndings, it has been
shown that 5-HT3 receptor antagonists ondanse-
tron and tropisetron dose dependently reversed the
haloperidol-induced VCMs and reduced haloper-
idol-induced wet dog shakes, further supporting
the possibility of an alteration in the serotonergic
system after chronic haloperidol treatment (Naidu
and Kulkarni, 2001b). It can be concluded that
these 5-HT receptors can serve as potential
therapeutic targets for the development of novel
molecules for the treatment and prevention of TD.
Catalepsy
The neuroleptic-induced state of catalepsy is
generally considered as an animal model of the
akinesia and rigidity seen in PD, which is
predictive of EPS for APDs. 5-HT is also
implicated in APD-induced catalepsy (Wadenberg,
1996). For example, different SSRIs attenuate
haloperidol-induced catalepsy in mice (Pires et al.,
2005). In addition, the 5-HT1A receptor agonists
8-OHDPAT and buspirone, and the 5-HT2A/2C
receptor agonists DOI and 1-(2,5-dimethoxy-4-
bromophenyl)-2-aminopropane (DOB), attenuate
D2 receptor-mediated catalepsy (Invernizzi et al.,
1988; Hicks, 1990; Neal-Beliveau et al., 1993;
Lucas et al., 1997). Moreover, the anti-cataleptic
effects of 8-OHDPAT and DOI are antagonized
by WAY 100635, a selective 5-HT1A receptor
antagonist (Bartoszyk et al., 1996), and mianserin,
a 5-HT2A/2C receptor antagonist (Neal-Beliveau
et al., 1993), respectively. In addition, 5-HT1A
receptor activation reduces the cataleptogenic
potential of novel antipsychotic agents such as
ziprasidone, aripiprazole, bifeprunox, SLV313,
SSR181507 and sarizotan (Kleven et al., 2005).
These ﬁndings strongly indicate that the seroto-
nergic system is involved in the onset of catalepsy.
There is strong evidence to suggest that (1) the
catalepsy produced by DA D1 or D2 receptor
antagonists can be completely antagonized by the
administration of 5-HT1A receptor agonists acting
at 5-HT1A autoreceptors in the DRN and (2) the
catalepsy produced by a DA D2 receptor antago-
nist can be completely antagonized by treatment
with a 5-HT2A/2C receptor agonist.
On the other hand, it has been shown that
clozapine inhibits the cataleptic response to
loxapine and olanzapine but does not induce
catalepsy by itself (Kalkman et al., 1997). In
addition, behavioural evidence shows that SB
228357, a selective 5-HT2B/2C receptor antagonist,
and ACP-103, a 5-HT2A receptor inverse agonist,
attenuated catalepsy produced by haloperidol or
risperidone (Reavill et al., 1999; Gardell et al.,
2007). On the other hand, the 5-HT2A and 5-HT2B
receptor antagonists MDL 100907 and SB 215505
did not reverse haloperidol-induced catalepsy.
These data suggest a role for 5-HT2C receptors in
the anti-cataleptic action of SB 228357. Thus, the
blockade of 5-HT2C receptors, instead of their
activation, would play a role in relieving the
neuroleptic EPS disturbance. This hypothesis is
further reinforced by the observation that the
5-HT2C receptor activation by Ro 600175 per se
induces catalepsy (Grottick et al., 2000).
Therefore, another interesting application of the
data regarding the functional role of 5-HT in the
basal ganglia is the possible use of 5-HT receptor
ligands in the treatment of drug-induced parkin-
sonian syndromes in relation to present efforts to
develop new atypical neuroleptics with afﬁnity for
brain 5-HT receptor subtypes.
Hitherto, only one piece of research has
investigated the effect of 5-HT6 receptor antagon-
ism on catalepsy and in rats with unilateral
6-OHDA lesions (Bourson et al., 1998). Ro
04-6790, a 5-HT6 selective antagonist, did not
induce catalepsy nor did it have any effect on
either haloperidol- or SCH 23390-induced cata-
lepsy. Administration of Ro 04-6790 was instead
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able to reverse rotational behaviour induced by the
muscarinic antagonists scopolamine and atropine
in unilaterally 6-OHDA-lesioned rats. These data
suggest that the 5-HT6 receptor is involved in the
control of cholinergic neurotransmission in the
striatum that is distal to DA transmission. A
possible mechanism could be an increase in ACh
release induced by 5-HT6 receptor blockades
directly or through modulation of GABA neuro-
transmission in the striatum, since 5-HT6 recep-
tors are expressed on GABA spiny neurons.
In addition, Ro 04-6790 alone did not induce
turning behaviour in the unilaterally lesioned
rat nor did it potentiate or inhibit ipsilateral
rotations induced by amphetamine. Furthermore,
Ro 04-6790 had no effect on the contralateral
rotations induced by L-DOPA. Therefore, 5-HT6
receptor afﬁnity does not account for the lack
of EPS — effects characteristic of clozapine-like
compounds (Bourson et al., 1998).
Conclusions
From the large amount of literature reviewed here,
it appears evident that the serotonergic neuro-
transmitter system plays a pivotal role in the
modulation of basal ganglia circuitry (Fig. 1), and
its dysfunction is involved in the pathophysiology
of PD and other motor disorders.
Among all the 5-HT receptors present in the
basal ganglia nuclei, the 5-HT1A/1B and 5-HT2A/2C
receptors are particularly important, because of
their localization and regulatory role on neuro-
transmitter release in many basal ganglia circuitry,
including GLUergic terminals in the SNc (Pineyro
and Blier, 1999). 5-HT1A receptor agonists have
the potential for being useful at different stages of
PD progression since they may provide sympto-
matic relief in early PD, and anti-dyskinetic
efﬁcacy in a later stage. Moreover, it has been
shown (Bezard et al., 2006) that 5-HT1A receptor
agonists could also present (partial) neuroprotec-
tion, partially blocking the excitotoxic cycle of
circuit-driven degeneration caused by the over-
activity of the STN afferents of DA neurons,
decreasing the hyperactivity of the remaining
DA neurons through opening of potassium
conductances and suppressing activity of the
vulnerability factor caspase-3 in the remaining
DA neurons.
Although several selective agents for 5-HT
receptors have been discovered, none has reached
the market for the treatment of motor disorders as
yet. However, several companies are very active in
5-HT receptor research in PD, although they have
concentrated on different receptor subtypes.
Nevertheless despite the promising ﬁndings, last
year, Merck KGaA decided to stop further
development of its late-stage development drug
sarizotan as a treatment for PD. The company
took the decision after examining the results of
two Phase III studies of sarizotan in advanced PD
patients with dyskinesia. A statement from Merck
KGaA said that the Phase III studies did not
conﬁrm earlier Phase II ﬁndings or the results from
preclinical studies. The two trials, PADDY 1 and
PADDY 2, investigated twice-daily dosing of
sarizotan 1-mg tablets, to investigate whether
the drug could achieve a 25% improvement in
dyskinesia symptoms, but it failed to meet this
efﬁcacy threshold.
From the data reviewed here, it should be clear
that drugs acting at the 5-HT2A/2C receptors might
be an important feature of the treatment of PD,
drug-related motor disturbances and the psychia-
tric symptoms often associated with these neuro-
logical disorders. Nevertheless, as happened for
the 5-HT1A receptors, no compounds selective for
5-HT2A/2C receptors have been released for the
treatment of major motor disturbances such as
PD. A glimmer of hope comes from the pharma-
ceutical company Acadia, which, in 2007, initiated
the ﬁrst Phase III pivotal trial with pimavanserin,
a 5-HT2A inverse agonist in PD patients with
PD psychosis, after having positively concluded
Phase II.
NS-2330, a triple monoamine reuptake inhibi-
tor, has shown therapeutic potential in PD. In
2006, NeuroSearch’s global partner Boehringer
Ingelheim has concluded that the results from
three completed Phase II clinical studies in PD did
not meet the company’s efﬁcacy criteria to proceed
with Phase III clinical development.
5-HT research is now more than 50 years old
and has generated a wealth of therapeutic agents,
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some of which have had a major impact on
disease management. SSRIs are among the most
widely prescribed drugs for treating depression
and a variety of other disorders, including
anxiety and social phobia. But we are a long
way from a serotonergic therapeutic intervention
for PD.
5-HT receptor research has generated detailed
information on the molecular biology and regional
and cellular localization of these receptors. A
major challenge now is to utilize this knowledge
to develop receptor-speciﬁc drugs and use the
information gained to better treat CNS disorders.
In addition, further clariﬁcation of the role of
5-HT transmission in the pathophysiology of
basal ganglia disorders is required since the overall
picture is still confusing. Furthermore, most of
the data came from animal studies and animal
models of PD that yielded contrary results
compared to clinical studies. This leaves room
for speculation about the real value of preclinical
research for clinical PD. Moreover, there are
also many avenues that remain unexplored, so
there are undoubtedly further advances to be
made.
Abbreviations
5-HIIA 5-hydroxy-indolacetic acid
5-HT serotonin
5-HTT 5-HT transporter
6-OHDA 6-hydroxydopamine
ACh acetylcholine
AHPs after-hyperpolarizations
APDs antipsychotic drugs
ATD acute tryptophan depletion
CNS central nervous system
DA dopamine
DBS deep brain stimulation
DRN dorsal raphe nucleus
EPN entopeduncular nucleus
EPS extrapyramidal symptoms
EPSCs excitatory postsynaptic currents
GLU glutamate
GP globus pallidus
GPe external segment of the GP
GPi internal segment of the GP
HFS high-frequency stimulation
IPSCs inhibitory postsynaptic currents
LAIs large aspiny interneurons
L-DOPA levodopa
LID L-DOPA-induced dyskinesia
MPTP 1-methyl 4-phenyl 1,2,3,6-tetrahy-
dropyridine
MRN medial raphe nucleus
MSNs medium spiny neurons
NMR nucleus raphe magnus
NRO nucleus raphe obscurus
NRP nucleus raphe pallidus
PLC phospholipase C
PPN pedunculopontino nucleus
SN substantia nigra
SNc SN pars compacta
SNr SN pars reticulata
SSRIs selective serotonin reuptake inhibi-
tors
STN subthalamic nucleus
TCAs tricyclic antidepressants
TD tardive dyskinesia
TPH tryptophan hydroxylase
VCMs vacuous chewing movements
VTA ventral tegmental area
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